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Abstract
Postoperative nausea and vomiting (PONV) commonly influence the perioperative experience of
general anesthesia patients. Although current guidelines suggest the use of combination therapy
for PONV prophylaxis, there is diminished application in practice. A potentially efficacious and
under-utilized medication being studied in combination with anti-emetics is haloperidol. The
main foci of this quality improvement project are to assess anesthesia provider knowledge and
attitudes regarding utilization of haloperidol for PONV prophylaxis in adult surgical patients.
This quality improvement project provides a segue to enhance anesthesia practice by diminishing
PONV using haloperidol. The primary methodology of the quality improvement project is to
implement an online educational module to anesthesia providers that focuses on the significance
of PONV in anesthesia practice and the impact of combination PONV prophylaxis utilizing
haloperidol. Qualtrics pre- and post-test surveys were employed to gauge the efficacy of the
educational module and to evaluate the influence on anesthesia provider knowledge and
attitudes. Findings pointed to a significant increase in anesthesia provider knowledge about
haloperidol PONV prophylaxis, and overall attitudes. The results showed an increase in
anesthesia provider knowledge and attitudes through implementation of the educational module
that presents the utilization of haloperidol as a pharmacological complement for PONV
prophylaxis.
Keywords: Postoperative Nausea and Vomiting, Haloperidol, Prophylaxis, Combination Therapy
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Significance of the Problem
Postoperative nausea and vomiting (PONV) is defined as nausea and vomiting that can
occur up to 24 hours postoperatively and in the post anesthesia care unit (PACU) where patients
recover after surgical procedures.1 In the perioperative setting, PONV is a potential risk factor
for all patients who opt for general surgery that involves utilization of anesthesia.1-2 Throughout
the years, a multitude of literature has pointed to promising PONV treatments that are still
implemented today.3 Although many treatments have shown to be efficacious in treating PONV,
research has fallen short of identifying a definitive gold standard for PONV management and
prophylaxis that includes haloperidol.3
With the persistent problem of PONV, healthcare systems and patients have had to face
increased costs, decreased patient satisfaction, adverse surgery outcomes, prolonged hospital
stays, and delayed PACU discharge.2,4-5 Combination therapy incorporating haloperidol for
PONV prophylaxis may contribute to a profound and positive transformation in the perioperative
arena.6-9 Guidance on the aforesaid subject may better equip anesthesia providers to combat the
negative outcomes prompted by PONV and diminish the occurrence of PONV overall.10 In this
dissemination, the investigator aims to answer the following question: (P) In adult surgical
patients (I) does an educational module on the utilization of haloperidol as a pharmacological
complement for PONV prophylaxis (C) versus no educational module (O) increase anesthesia
provider knowledge and attitude in implementing haloperidol as an adjunct treatment in the
management of PONV? The goal of this quality improvement (QI) project is to improve
anesthesia provider knowledge and attitude of PONV prophylaxis with an education module that
focuses on the use of haloperidol in combination PONV prophylaxis as modeled by an algorithm
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endorsed by an international panel of professional societies, including the American Society of
Anesthesiologists (ASA).
Background
The area in the brain associated with interpreting stimuli that cause nausea and vomiting
is found in the medulla.11 Various pathways provide input to the medulla emetic center such as
the following: the vestibular apparatus, chemoreceptor trigger zone (CTZ), visceral afferent
innervation of the gastrointestinal (GI) tract, solitary tract nucleus, cerebellum, and the cerebral
cortex.11-12 Of these pathways, one of the major characteristics of the CTZ is its connection to
drugs and toxins circulating the body due to its location outside of the blood-brain barrier and in
the fourth ventricle.11 Each of the aforesaid pathways involved in nausea and vomiting are
regulated by neurotransmitters and receptors.11 The vomiting reflex is found to be stimulated by
activation of receptors in the emetic center such as neurokinin-1 (NK-1), serotonin type 3,
acetylcholine (muscarine), dopamine, opioid, and histamine receptors.11,13
Various anesthetic, patient, and surgical factors help predict the potential incidence and
severity of PONV.1-2,14 Anesthetic PONV triggers depend on the utilization of volatile
anesthetics, nitrous oxide, opioid administration, anesthetic duration, and anesthetic technique.1
Particularly, patients most at risk are those who have received inhalational anesthetics and
opioids.2 It has been found that commonly used opioids, such as fentanyl and morphine,
contribute to PONV independent of other factors.2 Research demonstrates that early PONV, 0 –
2 hours postoperative, is mostly attributed to use of inhalational agents and delayed PONV has
been linked to opioid use 2 - 24 hours postoperative.14 General anesthetic technique has been
found to cause more PONV than regional anesthesia, and despite the lower occurrence of PONV
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with a total intravenous anesthetics (TIVA) technique, PONV still occurs.1 Other notable PONV
triggers increasing its incidence are nitrous oxide use and longer anesthetic exposure.1
Additionally, the type of surgery and surgical duration increase PONV risk related to
surgical factors.1 Surgeries linked to the highest PONV incidence are longer procedures and
those of gynecological, breast, ophthalmic, otorhinolaryngological, intra-abdominal, and
laparoscopic nature especially cholecystectomy.1,6 In combination with anesthetic and surgical
factors previously mentioned, patient factors, such as genetics, PONV history, gender, age, and
smoking status, also play a role in the incidence of PONV.1 The greatest PONV predictors in
order of influence are female gender, previous PONV history, first-degree relatives with PONV
history, non-smoking status, motion sickness history, and those who are less than 50 years old.1
Specific to children, PONV risk is increased by strabismus surgery, procedures lasting longer
than 30 minutes, age greater than 3 years old, and PONV family history.8 The International
Anesthesia Research Society demonstrates a relative depiction of intraoperative and
postoperative PONV risk factors amongst adults in figure 1, where the size of each segment is
proportional to the odds ratios of PONV associated with each risk factor.8
Figure 1. Adult Intraoperative and Postoperative PONV Risk Factors
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Currently, many medications are available in the anesthesia provider’s PONV
prophylaxis drug armamentarium. Literature classifies PONV medications as older generation,
newer generation, and non-traditional anti-emetics.6 The newer generation anti-emetics include
serotonin receptor and NK-1 receptor antagonists.6
Serotonin receptor antagonists are known for ligand binding and blocking the serotonin
5-HT3 receptor in the GI tract vagal afferents and the CTZ.6 The most used serotonin receptor
antagonist is ondansetron; however, others with similar characteristics are dolasetron,
tropisetron, and granisetron.6 Dizziness, headache, flushing, QT prolongation, and elevated liver
enzymes are potential side effects of serotonin 5-HT3 receptor antagonists.6,13 NK-1 receptor
antagonists, such as aprepitant, are known to block NK-1 receptors in the peripheral nervous
system, area postrema, and nucleus tractus solitarius preventing substance P, the natural ligand,
from binding.8,12 While the NK-1 receptor blocker, aprepitant, shows promise in PONV
prevention, other medications in this category, such as casopitant and rolapitant, have not been
approved for use.8 Unlike the serotonin 5-HT3 receptor antagonists in the newer generation antiemetics, aprepitant does not prolong QT and fails to cause sedation like some other anti-emetic
medications.13 Corticosteroids have been classified as non-traditional anti-emetics; however,
their mechanism of action in this respect is unknown.6 There is suspicion that the antiinflammatory and endorphin releasing properties of corticosteroids may contribute to their antiemetic effect.6 Dexamethasone is the most used corticosteroid for PONV and is not associated
with side effects at doses used for PONV prevention.6
Older generation anti-emetics include phenothiazines, antihistamines, anticholinergics,
benzamides, and butyrophenones.6 Phenothiazines, such as chlorpromazine, promethazine,
prochlorperazine and perphenazine, are responsible for antagonizing dopamine D2 receptors in
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the CTZ.6 Side effects of phenothiazines are sedation, restlessness, hypotension, neuroleptic
malignant syndrome (NMS), and anticholinergic effects.6 Dopamine receptor blocking agents are
also capable of precipitating extrapyramidal symptoms (EPS), which can present as abnormal
muscle tone and movements.15 Akathisia, tardive dyskinesia, parkinsonism, and dystonia are
grouped together as physical manifestations of EPS that can be described as tremors, rigidity,
and bradykinesia.15 The physical manifestations of EPS have been tied to psychological
symptoms such as cognitive impairment, apathy, and dysphoria.15
Antihistamines, such as diphenhydramine, dimenhydrinate, hydroxyzine, and cyclizine,
affect the nucleus of the solitary tract histamine H1 receptors and the vestibular apparatus by
antagonizing acetylcholine receptors.6 Side effects of antihistamines include dry mouth and
sedation.6 Anticholinergics, such as scopolamine and atropine, work on the pons and cerebral
cortex blocking cholinergic and muscarinic receptors in the central nervous system.6 Blurred
vision, dry mouth, mydriasis, hallucinations, sedation, urinary retention, disorientation,
confusion, and cholinergic syndrome are potential side effects of anticholinergics.6 Among the
benzamides, metoclopramide is administered the most and is known for its prokinetic
properties.6 Metoclopramide specifically antagonizes GI tract dopamine D2 receptors and affects
the same receptors in the area postrema and CTZ.6 Side effects associated with benzamide use
include restlessness, sedation, hypotension, bradycardia, tachycardia, and EPS.6
Butyrophenones, such as haloperidol and droperidol, are recognized to work at the area
postrema and CTZ as dopamine D2 receptor antagonists.6 Haloperidol has been underutilized in
anesthesia; however, droperidol provided a sufficient anti-emetic treatment before it was labeled
with a black box warning due to sudden cardiac death.6 Butyrophenones rarely cause EPS and
have been associated with QT prolongation, torsades de pointes, hypotension, sedation, NMS,
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urinary retention, nightmares, and visual disturbance.6,8,13,16 As haloperidol is the featured focus
of this quality improvement project, the topic requires further dissemination on its
pharmacological and biochemical qualities. Upon the synthesis of haloperidol in 1958 by Janssen
Pharmaceutical research laboratories, the original aim was for use as a neuroleptic medication.17
The birth of haloperidol contributed to the knowledge base of psychiatry through understanding
of neurobiology and psychopharmacology.17 The initial indications for haloperidol use were for
hallucinations, delirium, and psychomotor related diseases.18
When researchers studied haloperidol’s properties on dogs in 1976, it was found that it
has a long duration of action of 64 hours when administered via oral and subcutaneous routes.17
Equipotency of both oral and subcutaneous routes of haloperidol administration was found to
occur after the fourth hour at 0.03 milligrams (mg)/kilogram (kg), and research supports oral
absorption and potency at this dose.17 Haloperidol’s onset of action was shown to differ based on
route of administration; the onset of the subcutaneous route was faster than the oral route, which
peaked after four hours.17 A further study showed that haloperidol is a typical neuroleptic that
exhibits sedative and alpha-adrenergic inhibiting properties, unlike atypical neuroleptics.17 From
a biochemical standpoint, it first became known that haloperidol blocks dopamine receptors
when the 1976 study showed inhibition of dopamine production on cyclic adenosine
monophosphate (cAMP).17
When haloperidol’s neuroleptic profile was studied, researchers explored the anti-nausea
and anti-emetic properties of a single 1 mg intramuscular injection of haloperidol in a doubleblind placebo-controlled trial in 1975 involving a total of 62 patients.19 In the study by Barton et
al,19 male and female subjects had surgical procedures ranging from tubal ligation to mandibular
reconstruction and received anesthetic agents available during this period such as cyclopropane,
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sodium thiopental, nitrous oxide, halothane, ether, and fluroxene. Thirty minutes after
haloperidol administration, 71% of subjects did not experience nausea and 83% failed to vomit,
while 29% of placebo patients experienced vomiting and 20% expressed nausea, thus showing
haloperidol’s superior treatment of PONV over placebo.19 After an hour, subjects in the
haloperidol group did not experience any vomiting.19 Despite the known side effects of
haloperidol seen at high doses, subjects in the Barton et al19 study who received a low dose of
haloperidol did not experience hypotension or EPS.
Since the 1970s, more research has been conducted which focuses on haloperidol and its
ability to prevent PONV. In 2005, the American Association of Nurse Anesthetists (AANA)
journal featured a publication by Smith and Wright that highlighted haloperidol’s role in PONV
prophylaxis.16 After a review of prior studies, it was established that haloperidol’s PONV
prophylactic potency began within 30 minutes of administration and its duration of action is 4
hours.16 Smith and Wright16 also informed that efficacious dosages of haloperidol for PONV
prophylaxis were 0.015 mg/kg IV and 0.007 mg/kg IM, where the IM route was more
efficacious. At that time, studies pointed to PONV antiemetic doses to be between 0.5 mg to 1
mg.16 According to Smith and Wright,16 haloperidol use was linked to the presentation of adverse
effects previously mentioned when it was given at high doses in psychiatric practice, such as 35
mg or more within a 24-hour period. At low doses used for PONV, the risk of adverse effects is
minimal.16 Despite the low risk, it is best advised to avoid haloperidol in patients with QT
prolongation, congestive heart failure, acute/chronic dysrhythmias, electrolyte disturbances,
cardiac hypertrophy, acute cardiac syndromes, Parkinson’s disease, and NMS.16 Additionally,
patients taking monoamine oxidase inhibitors and tricyclic antidepressants should refrain from
taking haloperidol.16
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In 2008, Wang et al18 studied the PONV efficacy of haloperidol in 150 women who had
undergone ambulatory laparoscopic surgery that involved the same general anesthetic with
tracheal intubation and administration of fentanyl, propofol, rocuronium, desflurane with
oxygen, neostigmine, and atropine. Wang et al,18 conducted a double-blind randomized placebocontrolled study in women who received 1 mg of IV haloperidol, 0.625 mg of IV droperidol, or a
saline placebo. As a result, subjects who received haloperidol and droperidol demonstrated a
similar incidence of PONV at 31% and 32% respectively, which was lower than the placebo
group at 62%.18 Additionally, subjects in the haloperidol and droperidol groups required less
rescue anti-emetics than those in the placebo group who required 4 mg of ondansetron.18 At such
a low dose of haloperidol, subjects did not experience QT prolongation, EPS, or sedation.18
Yang et al20 explored the PONV prevention efficacy of haloperidol and compared the
timing of administration during the perioperative period in a randomized, double-blind study of
women undergoing plastic, gynecologic, breast and thyroid surgeries. Ninety-four women
participated in this study who had a history of PONV and/or motion sickness, were non-smokers,
and were classified as a physical status score of I or II by the ASA.20 Subjects in the Yang et al20
study received 2 mg of haloperidol IV 30 minutes before the termination of surgery or during
anesthetic induction and had undergone general anesthesia with tracheal intubation using
fentanyl, propofol, rocuronium, sevoflurane with oxygen, neostigmine, and atropine. Findings
yielded no difference in the anti-emetic efficacy of haloperidol when administered at different
times, which was suspected to be due to haloperidol’s long elimination half-life of 12 – 35 hours
that typically averages 16 hours, which is unlike droperidol’s shorter elimination half-life.20 At
such low haloperidol doses, subjects did not experience significant sedation nor cardiac
arrhythmias.20
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Scope of the Problem
Despite the availability and use of current treatments, PONV affects over 25 – 30% of
surgical patients.6 When considering surgical patients at risk of experiencing PONV, the
incidence of PONV has been found to be as high as 80%.1-2 Although the severity of PONV has
decreased, the incidence has not.6 Recently, research has found that the incidence of PONV has
been amplified by the growth observed in ambulatory surgery.21 Elvir et al21 also brings to the
forefront that pressures promoting timely discharge and mobilization after surgery have been
catalysts in the PONV issue.
In the adult population, the PONV incidence has been noted to be the highest at 40 – 77%
after laparoscopic procedures.6 Otorhinolaryngological and ophthalmic procedures among adults
have been tied to a 71% incidence of PONV, while intra-abdominal surgeries came in close at
70%.6 Additionally, gynecological surgeries ranked a PONV incidence of 58% and breast
surgeries were linked to a 50 – 65% PONV occurrence.6 In the pediatric population, the patients
who demonstrated the highest risk for PONV at 85% were those who had strabismus surgery.6
Pediatric patients who experienced middle ear surgeries and tonsillectomies were also considered
high risk for developing PONV.6
Consequences of the Problem
Although PONV is non-fatal, it is notorious for straining healthcare systems through
increased costs and causing undesirable health outcomes that have led to decreased patient
satisfaction.5,14 According to Habib and Gan,6 PONV is ranked in the top 10 most unfavorable
outcomes after surgery. Unpleasant symptoms associated with PONV contributing to
considerable patient morbidity and distress include esophageal rupture, wound dehiscence,
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aspiration, decreased oral intake, electrolyte disturbances, dehydration, bleeding, venous
hypertension, and airway compromise.1,5,11,14
Among patients who have experienced PONV, many have been met with delayed PACU
discharge.1-2,6-7,11 Patients who have succumbed to severe PONV have shown to be subjected to
preventable hospital admission that prolonged hospital stays.2,5-7,11 Researchers found that the
hospital length of stay postoperatively increased by 25% in general anesthesia patients and 79%
in monitored anesthesia care (MAC) patients who experienced protracted PONV.6
The overall effect of PONV has contributed to higher costs associated with an increased
demand for nursing labor and hospital resources.12 The healthcare costs accrued due to lengthy
hospital stays and delayed PACU discharge secondary to PONV were discovered to surpass the
cost of prophylactic anti-emetic treatment.1 Wang et al18 pointed out that the typical cost of
haloperidol in Taiwan is $0.30 in US dollars that is significantly less than ondansetron, which is
commonly used as a rescue anti-emetic and can cost as much as $7.47 in US dollars.
While healthcare costs are significant, delayed PACU discharge, hospital admission, and
adverse surgery outcomes have also led to decreased patient satisfaction among those affected by
PONV.1,12 Research has demonstrated that PONV prophylaxis has been tied to improved patient
satisfaction and shows to be cost-effective especially in high-risk patients.12 Surgical patients
who were studied valued PONV prevention so much that they were willing to pay $56 - $100 to
circumvent the unfavorable effects of PONV with a hypothetical anti-emetic that provided a
complete response in PONV prophylaxis.4
Knowledge Gaps
According to Eberhart et al,22 no single drug is credited with the power to diminish
PONV to a tolerable level. Considering the high incidence and persistence of PONV, the use of a
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sole agent for PONV prevention has been advised against due to the potential for positive
outcomes with a combination approach to PONV prophylaxis.7 Therefore, research advocates for
the utilization of combination therapy for PONV prophylaxis with the understanding that
antagonizing multiple receptors associated with PONV can provide superior PONV prevention
in surgical patients.7-9,23 Although there is significant literature available today that addresses
PONV, the utilization of PONV combination therapy in surgical patients is lacking in practice.9
Dewinter et al9 published that there is limited knowledge of PONV guidelines and adherence to
published guidelines is not consistent. In efforts to address the adverse effects of nausea and
vomiting along with decreased compliance, PONV algorithms were simplified by Dewinter et al9
researchers with the goal of ultimately reducing the incidence of PONV.
Proposal Solution
In 2018, the British Journal of Anesthesia delineated a PONV algorithm depicted in
figure 2 that recommended using up to three anti-emetics, droperidol, ondansetron, and
dexamethasone, in PONV prophylaxis depending on PONV risk stratification.9 The British
Journal of Anesthesia simplified this algorithm, which is highlighted in figure 3. Following this,
the International Anesthesia Research Society expanded on previously published iterations on
PONV prophylaxis and suggested guidelines in 2020 that modeled haloperidol’s medication
class in PONV combination therapy.8 The most recent PONV practice guideline update
published by the International Anesthesia Research Society is endorsed by multiple international
professional societies, including the ASA and the AANA. 8 Additional anesthesia experts
supporting the PONV practice guidelines published by the International Anesthesia Research
Society include the following societies: the American Society for Enhanced Recovery, the
American Society of Health Systems Pharmacists, the American Society of Peri Anesthesia
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Nurses, the American Academy of Anesthesiologist Assistants, the American College of Clinical
Pharmacy, American College of Clinical Pharmacy Perioperative Care Practice and Research
Network, the Australian Society of Anesthetists, the Brazilian Society of Anesthesiology, and the
Chinese Society of Anesthesiology.8
The guidelines previously mentioned suggest utilization of anti-emetics based on risk
stratification similar to the British Journal of Anesthesia.8-9 Per the International Anesthesia
Research Society, the recommended guidelines for PONV management in adult surgical patients
suggests administering two agents if exhibiting one to two risk factors for PONV and giving
three to four agents if there are greater than two risk factors.8 The recommended prophylactic
PONV agents highlighted for adult use by the most recent algorithm in 2020 are meant to be
selected from different drug classes, which include the following: 5-HT3 receptor antagonists,
antihistamines, corticosteroids, dopamine antagonists, NK-1 receptor antagonists, and
anticholinergics highlighted in figure 4.8 Additional prophylactic approaches are also considered
in the ASA endorsed PONV adult algorithm, such as propofol anesthesia and non-pharmacologic
measures like acupuncture.8
Among children, the PONV prophylaxis guideline published by the International
Anesthesia Research Society also involves risk stratification similar to that of adults except
recommended agents are 5-HT3 antagonists and dexamethasone as depicted in figure 5.8
According to Gan et al,8 a child with no risk factors is classified as low risk and may require one
agent, 5-HT3 antagonist or dexamethasone, all the while, a child exhibiting one to two risk
factors, medium risk, suggests combining use of dexamethasone and a 5-HT3 antagonist. Among
high-risk children who exhibit greater than three risk factors, the International Anesthesia
Research Society recommends combining a 5-HT3 antagonist, dexamethasone, and TIVA.8
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Following prophylaxis with dexamethasone and/or 5-HT3 antagonists in children, it is suggested
to utilize more agents from different classes as needed for PONV rescue treatment.8 The
International Anesthesia Research Society summarizes common combinations of anti-emetics
recommended for PONV pharmacologic combination therapy for adults and children in figure
6.8
Figure 2. British Journal of Anesthesia Risk Stratified PONV Algorithm

Figure 3. British Journal of Anesthesia Simplified PONV Algorithm
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Figure 4. International Anesthesia Research Society PONV Guidelines for Adults

Figure 5. International Anesthesia Research Society PONV Guidelines for Pediatrics
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Figure 6. International Anesthesia Research Society PONV Medication Combinations

Although haloperidol is not FDA approved specifically for PONV prevention, the black
box warning placed on droperidol has led to its declined use and there has been an increased
interest in haloperidol utilization as an alternative.8-9 Although suggested guidelines and
algorithms exist, there is no gold standard combination PONV treatment including haloperidol
that is being followed consistently to lower the PONV incidence below the current occurrence in
all surgical patients.8-9 Taking this into consideration, extensive research highlights the value of
haloperidol in PONV prophylaxis and combination PONV therapy. Among the suggested PONV
prophylaxis drug combinations supported by the international panel of anesthesia experts in
2020, haloperidol is found to be a promising option when grouped with ondansetron and/or
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dexamethasone.8 The quality of evidence used to validate the aforementioned pharmacological
therapies of PONV agents is high, which suggests supportive literature exists for the basis of this
algorithm.8 According to recent recommendations by Gan et al,8 the most efficacious dose of IV
or IM haloperidol ranges between 0.5 to 2 mg during the perioperative period. Gan et al8 found
that when 1 mg of haloperidol was given after the induction of anesthesia, there were no EPS
reported and at this dose, 4 mg of ondansetron was not superior in PONV prophylaxis at 4 and
24 hours following administration. Gan et al8 also showcased that although there was an
associated increase in sedation, the PONV risk was no different in PACU and over the course of
24 hours if 2 mg of haloperidol was administered at the end of surgery or at induction.
In 2007, Rüsch et al23 explored the additive effect of anti-emetics used in combination
with other anti-emetic pharmacological treatment in a randomized study. Researchers in the
Rüsch et al23 study found that dexamethasone enhanced the PONV prophylaxis effect of
haloperidol and dolasetron. Among 242 patients undergoing elective procedures under general
anesthesia, both IV haloperidol and dolasetron showed similar efficacy in PONV prevention and
demonstrated superior effect when either was combined with dexamethasone versus when used
as sole agents.23
Dagtekin et al24 conducted a randomized and double-blinded study in 2009 that explored
haloperidol used as a sole agent for PONV versus haloperidol used in combination with
ondansetron. In the Dagtekin et al24 study, 60 patients undergoing strabismus or retinal surgery
received 10 micrograms (mcg)/kg of haloperidol with 0.1 mg/kg of ondansetron or solely 10
mcg/kg of haloperidol. Findings published by Dagtekin et al24 reported that haloperidol used in
combination therapy provided better PONV results than when used alone.
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Despite the saturation of literature, supportive evidence provided still validates
haloperidol’s essential role in PONV prophylaxis in adult surgical patients when integrated with
combination anti-emetic therapy. The efficacy of haloperidol in combination with
pharmacological therapy among adult surgical patients will create a paradigm shift in the
knowledge and attitude of PONV prophylaxis among anesthesia providers in utilizing the
empirical evidence for best practice in the prevention of PONV.
Summary of the Literature
Eligibility Criteria
Selection of studies for this literature review required a more expansive search due to
saturation of research. Despite search limitations, inclusion and exclusion criteria were modified
to generate sufficient literature with guidance from context experts. Meta-analyses, literature
reviews, and systematic reviews were considered as exclusion criteria for this dissemination.
Parameters considered as inclusion criteria included literature published within the past fourteen
years that was obtainable as full text and followed a randomized clinical trial design. Primary
studies selected centered on the efficacy of haloperidol for PONV prophylaxis in combination
therapy and as a sole agent. The Florida International University (FIU) library facilitated the
search by providing access to most databases utilized. Complemented by Boolean operators,
keywords used in this search included variations and combinations of the following: Haloperidol,
Postoperative Nausea and Vomiting, Prophylaxis, and Combination Therapy.
Information Sources
MEDLINE (ProQuest) and the Cumulative Index to Nursing and Allied Health Literature
(CINAHL) were the primary databases employed. The Directory of Open Access Journals
(DOAJ) accessed via Florida International University (FIU) Library services and the Anesthesia
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& Analgesia Journal also provided a supplemental search avenue for literature not obtained via
CINAHL and MEDLINE.
Search Strategy
Initially, the keyword search in MEDLINE and CINAHL included the following terms:
(haloperidol OR haldol) AND (PONV OR postop* nausea and vomiting) AND (prophylaxis or
prevention) AND (combination therapy OR combination). Consequently, both databases yielded
a total of 33 articles, 7 from CINAHL and 26 from MEDLINE. Upon modification of the
publication time frame to range from 2008 – 2021, the search was refined yielding a total of 27
articles. Four duplicate articles were excluded resulting in 23 articles left for analysis. Of the
remaining 23 articles, further investigation led to exclusion of 17 articles that did not meet
inclusion criteria. Research articles excluded did not meet inclusion criteria based on the type of
publication, meta-analysis or systematic review, or failing to include haloperidol in the studies. A
total of 6 articles were selected for use from CINAHL and MEDLINE that focused on
haloperidol’s use in combination with other anti-emetics.
Additionally, a search within the Directory of Open Access Journals (DOAJ) – Not for
CDI Discovery, and the official journal of the International Anesthesia Research Society,
Anesthesia & Analgesia, was done. The DOAJ search included using the following terms:
(haloperidol OR haldol) AND (PONV OR postop* nausea and vomiting). As a result, the DOAJ
yielded over 866 articles. When search parameters were modified to include more recent
literature from 2019 – 2021 that was peer reviewed and available online, the DOAJ yielded 179
articles. Of the 179 articles generated by the DOAJ, one article met inclusion criteria that
discussed the PONV efficacy of haloperidol and was a randomized controlled trial. The search
within Anesthesia & Analgesia also included using the following terms: (haloperidol OR haldol)
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AND (PONV OR postop* nausea and vomiting). As a result, Anesthesia & Analgesia yielded 19
articles. Of the 19 articles generated, one article met inclusion criteria that discussed the PONV
efficacy of haloperidol and was a randomized controlled trial.
Study Characteristics
The eight articles identified for analysis studied fundamental topics in question. The
primary subject involving PONV prophylaxis using haloperidol in combination therapy was
explored by Benevides et al25 in 2013, Joo et al26 in 2015, Chaparro et al27 in 2010, Chu et al28 in
2008, Wang et al29 in 2012, Grecu et al30 in 2008, and Feng et al31 in 2009. These researchers
aimed to investigate the role of combined PONV therapy integrating haloperidol used for
varying surgical procedures amongst adults. One article studied haloperidol used in combination
with ondansetron and dexamethasone, four articles focused on assessing the PONV efficacy of
haloperidol when used with dexamethasone, and two articles investigated haloperidol in
combination with ondansetron. The eighth article by Dağ et al,32 focused on analyzing the PONV
efficacy of haloperidol used as a sole agent in adult female surgical patients in 2019. Overall, all
studies examined the adult population during their postoperative experience following general
anesthesia, included haloperidol in the PONV prophylactic treatment, and were randomized
clinical trials.
Results of Individual Studies
Effect of Low-Dose Haloperidol as a Sole Agent on PONV
Among the most recently published literature on PONV in 2019, Dağ et al32 sought to
find the most effective dose of haloperidol that provided the least amount of side effects and
yielded the best PONV prevention. Supplemental research by Dağ et al32 also aimed to explore
patient satisfaction who participated in the study. Dağ et al32 study meets criteria for
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classification as experimental with good, level I evidence due to randomized assignment of
treatment groups and utilization of a traditional control group. All participants in this study,
subjects, anesthesiologists, and postoperative evaluators, were also blinded to the allocation of
treatment groups, which diminished bias.32 Dağ et al32 included 250 female patients who were
scheduled for laparoscopic abdominal hysterectomy, between 19 and 70 years old, and were
given a physical classification score of ASA I – II. Subjects excluded from this study were those
who were allergic to opioids, had a nasogastric tube for 24 hours prior to surgery, were given
anti-emetics 24 hours before surgery, needed a large intestinal resection, had a haloperidol
contraindication, or had a history of cranial, cardiac, renal, hepatic, or lung disease.32
Participating subjects were randomly assigned to five groups that received different doses, 0.25
mg, 0.5 mg, 1 mg, or 2 mg, of haloperidol parenterally or the saline placebo.32 All patients
received midazolam preoperatively and had undergone general anesthesia with tracheal
intubation that involved administration of propofol, fentanyl, rocuronium, sevoflurane, nitrous
oxide, oxygen, neostigmine, and atropine intraoperatively.32 Additionally, participants received
30 mg of morphine for PCA at the termination of surgery.32 Data was collected from all subjects
beginning at 30 minutes postoperatively and was followed by continued observation for 24
hours; researchers documented outcomes hourly for the first 4 hours, every 2 hours until the sixth
hour, every 6 hours until the twelfth hour, and then every 12 hours until 24 hours
postoperatively.32 During this time, researchers recorded vitals, side effects, sedation level,
patient satisfaction, and need for anti-emetics.32 Researchers utilized mean, standard deviations,
normality tests using Kolmogorov-Smirnov test with Lilliefors correction, Kruskal-Wallis test,
Mann-Whitney U test, Monte Carlo test, and Chi-square test to analyze data.32 Data collected
was further analyzed at a 95% confidence level using version 17.0 of Statistical Package for the
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Social Sciences (SPSS) for windows.32 The incidence of nausea differed 2 hours postoperatively
and was recorded as statistically significant at P > 0.008; 28% of patients in group V given 0.25
mg of haloperidol, 14% of patients in group IV given 0.5 mg of haloperidol, 14% in group III
given 1 mg of haloperidol, 4% of patients in group II given 2 mg of haloperidol, and 26% of
patients in group I given the placebo had nausea.32 There was also a statistically significant
difference at P = 0.000 of nausea incidence between 2 and 24 hours after surgery; 28% of
patients in group V given 0.25 mg of haloperidol, 6% of patients in group IV given 0.5 mg of
haloperidol, 2% in group III given 1 mg of haloperidol, 4% of patients in group II given 2 mg of
haloperidol, and 18% of patients in group I given the placebo had nausea.32 Two hours
postoperatively, researchers observed a statistically significant difference at P = 0.009 among
groups regarding the incidence of vomiting; 16% of patients in group V given 0.25 mg of
haloperidol, 10% of patients in group IV given 0.5 mg of haloperidol, 6% in group III given 1
mg of haloperidol, 0% of patients in group II given 2 mg of haloperidol, and 20% of patients in
group I given the placebo experienced vomiting.32 Between 2 and 24 hours after surgery, groups
did not show a statistically significant difference at P = 0.218 in regards to the incidence of
vomiting.32 Ultimately, there was a statistically significant difference among treatment groups;
the placebo group experienced the highest anti-emetic need at 40% while the subjects treated
with haloperidol required fewer rescue anti-emetics.32 According to Dağ et al,30 6% of
participants who received 2 mg of haloperidol in group II, 8% of participants who received 1 mg
of haloperidol in group III, 14% of participants who received 0.5 mg of haloperidol in group IV,
and 28% of participants who received 0.25 mg of haloperidol in group V needed an additional
anti-emetic, which was statistically significant at P < 0.05.32 The primary findings from the Dağ
et al32 study highlighted that the optimal and efficacious dosages of parenteral haloperidol for
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PONV range from 0.5 mg to 2 mg, despite literature in 2005 by Smith and Wright that presented
a narrower range from 0.5 mg to 1 mg.16 Participants in group II who received the highest dose
of haloperidol of 2 mg experienced the highest level of patient satisfaction that was also
statistically significant at P < 0.05.32 Researchers also found that at such low doses no QT
interval prolongation or arrhythmias were observed, and participants did not experience differing
levels of sedation or variation of vitals at all doses.32
Combined Effect of Haloperidol, Ondansetron, and Dexamethasone on PONV Versus Sole
Use of Ondansetron or Dexamethasone with Ondansetron
While the Dağ et al32 study focused on haloperidol’s role in PONV as a sole agent, further
data on the subject can be found in the 2013 study by Benevides et al25 that considered other antiemetics in combination with haloperidol. Benevides et al25 conducted a randomized doubleblinded trial on a total of 90, male and female, laparoscopic sleeve gastrectomy (LSG) patients,
which aimed to evaluate the efficacy of haloperidol, dexamethasone, and ondansetron in
combination therapy to prevent PONV and the need for rescue anti-emetics. Secondary research
in this study also involved evaluating the need for analgesics and postoperative IV fluids,
hospital length of stay, and incidence of adverse effects.25 Subjects included in the Benevides et
al25 study were those who had an ASA score of I – III, qualified with a body mass index (BMI)
greater than or equal to 35 kg per meter squared (m2) and were at least 18 years old. Excluded
participants were those who received opioids/anti-emetics/hormonal anti-inflammatory
medications 24 hours before surgery; experienced serious perioperative complications such as
hemorrhage warranting transfusions, cardiac arrest, and shock; struggled with a psychiatric
disorder; and reported a migraine history.25 Other criteria for subject exclusion in the Benevides
et al24 study were contraindication or allergy to ondansetron, haloperidol, or dexamethasone.
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Researchers in the Benevides et al25 study utilized computer-generated randomization lists to
allocate subjects to treatment groups; however, did not consider a traditional placebo control
group since it was noted that knowingly withholding prophylactic PONV medication would be
unethical, especially in surgeries of this nature with a high risk of PONV. Therefore, research
conducted by Benevides et al25 follows a quasi-experimental design since it uses a nonequivalent control group and is classified as good, level II evidence. With the goal of
diminishing bias, surgeons, patients, and anesthesiologists were not privy to the allocation of
subjects to treatment and comparison control groups.25 Patients participating in this study were
administered 2 mg of IV haloperidol, 8 mg of IV ondansetron, and/or 8 mg of IV dexamethasone
based on the groups assigned.25 The Benevides et al25 study comparison control group labeled
group O that received 8 mg of ondansetron, while treatment groups were the following: group
DO was given 8 mg of dexamethasone plus 8 mg of ondansetron, and group HDO received 2 mg
of haloperidol with 8 of ondansetron plus 8 mg of dexamethasone. Administration of
ondansetron occurred 20 to 30 minutes before surgery was complete, all the while haloperidol
and dexamethasone were given after anesthetic induction.25 All participants who had undergone
general anesthesia experienced the following: induction with propofol, fentanyl, cisatracurium,
and tracheal intubation; maintenance with a remifentanil infusion, a mixture of inhalation gases:
isoflurane, oxygen, and air, and additional cisatracurium as needed; and neuromuscular blockade
reversal with neostigmine and atropine.25 Postoperative feeding consisted of a liquid diet made of
a residue-free broth and pain management involved 30 mg of ketolorac plus 20 – 30 mg of
dipyrone at induction and every 4 – 8 hours thereafter, in addition to 2 – 3 mg of IV morphine
for mild pain experienced in the PACU, and 5 mg of subcutaneous (SC) morphine given prior to
transfer out of PACU if pain was moderate to severe.25 All participants were also eligible for
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rescue anti-emetics, 10 mg of IV metoclopramide and/or 30 mg of IV dimenhydrinate, as
needed.25 Throughout the study, researchers collected primary data at different times
postoperatively, 24 – 36, 12 – 24, 2 – 12, and 0 – 2 hours, and telephone questionnaires were
administered to patients who were discharged prior to 36 hours since surgery.25 Data analysis
involved the use of analysis of variance, Tukey test, Kruskal-Wallis test, Mann-Whitney test,
Chi-square/Fischer’s exact test, Kaplan-Meier curves, and log-rank test.25 As a result, statistically
significant differences were found among study groups in the Benevides et al25 study. The HDO
group experienced less nausea at 23.7% after 0 – 2 hours and 53.3% after 0 – 36 hours
postoperatively compared to group O that experienced nausea 56.7% after 0 – 2 hours and 86.7%
after 0 – 36 hours, with a P = 0.016 and P = 0.015 at each of the time periods, respectively.25
Researchers also found that there was a statistically significant difference of P = 0.015 in the
incidence of vomiting at 0 – 36 hours postoperatively between group O with 53.3% and the HDO
group with 20%.25 Just as important, participants in the HDO group were able to wait a longer
period of time before administration of a rescue anti-emetic unlike group O that required sooner
rescue; this finding was also statistically significant at P = 0.006.25 Throughout the course of the
36-hour observation period, 50% of the HDO group, 40% of the DO group, and 20% of the O
group did not exhibit the need for rescue therapy.25 The Benevides et al25 trial showed that
although hospital length of stay did not change for this surgical population, there was a lower
PONV incidence and the use of rescue anti-emetics was reduced in groups that utilized a
combined PONV treatment approach including haloperidol, ondansetron, and dexamethasone.
Findings by Benevides et al25 also showed a decreased need for morphine pain management and
IV fluids when using this combination therapy. Although some participants commonly reported
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dizziness and headache, the adverse effects were minimal and not significantly focused on in this
study due to lack of influence on primary results.25
Combined Effect of Haloperidol and Dexamethasone on PONV Versus Sole Use of
Dexamethasone
In 2015, Joo et al26 published a randomized, double-blind dose-response and placebocontrolled study that focused on evaluating PONV efficacy with haloperidol in combination with
dexamethasone among 150 female patients who had undergone gynecological laparoscopic
surgery. Inclusion criteria for subjects considered were ASA score of I – II, age of 20 – 65 years,
use of IV PCA, and non-smoking status.26 The previously delineated inclusion criteria correlates
with the presence of 3 Apfel PONV risk factors: non-smoking status, opioid use, and female.26
Participants were excluded if they met any of the following criteria: hypersensitivity to
medications used, BMI greater than 35 kg/m2, chronic use of a dopamine antagonist,
steroid/opioid intake within 7 days of surgery, anti-emetic use 24 hours prior to study, cardiac
arrhythmias, kidney/liver/GI/psychiatric disease, diabetes requiring insulin, and inability to
utilize a PCA device.26 Researchers studied subjects who were randomly assigned to two
treatment groups; the H1 group received 1 mg of IV haloperidol, the H2 group received 2 mg of
IV haloperidol, and the H0 control group received IV saline.26 Each group had a total of 50
subjects to satisfy an alpha level of 0.05.26 Therefore, this experimental study qualified as good,
level I evidence due to the presence of a traditional control group. Patients, anesthesiologists, and
staff evaluating postoperative outcomes were blinded to the allocation of study groups, which
was decided by computer-generated codes.26 The computer-generated codes were placed in
opaque envelopes given to a nurse anesthetist not participating in the evaluation of subjects who
prepared the medications to be given.26 This study’s blinded design allowed for researchers to
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diminish bias as much as possible to prevent compromise of findings. Joo et al25 participants
underwent general anesthesia that involved tracheal intubation and administration of
remifentanil, propofol, rocuronium, sevoflurane, air/oxygen, pyridostigmine, and glycopyrrolate.
All subjects in the Joo et al26 study were administered 5 mg of IV dexamethasone during
induction, which was received in combination with 1 or 2 mg of IV haloperidol 30 minutes
before the end of anesthesia, or alone if solely receiving saline in the control group. At the
termination of surgery, participants were administered 1 gram (g) of IV acetaminophen in PACU
and started on PCA with 120 mg of ketolorac and 1 mg of fentanyl once discharged from PACU
2 hours later.26 Data was collected at 2 – 24 hours and 0 – 2 hours postoperatively where the
primary focus was on PONV incidence; however, subjects were also evaluated for additional
factors such as the need for rescue anti-emetics/analgesics, degree of pain, sedation level, and
occurrence of adverse effects of neurological/cardiovascular nature.26 Data analysis involved
one-way analysis of variance (ANOVA), Bonferroni test, Chi-square test, and SPSS version 15.0
for windows.26 Earlier in the PACU time frame at 0 – 2 hours postoperatively there was no
difference observed between groups H2 and H0; however, within 2 – 24 hours postoperatively,
subjects in the H1 and H2 group experienced less PONV, 22% and 20% respectively, than the
H0 group that scored a higher incidence of PONV at 42%.26 Results after 24 hours demonstrated
that there was a statistically significant difference at P = 0.003 in PONV incidence between
treatment groups, H1 and H2, and the control group, H0, where 29%, 24%, and 54% of
participants experienced PONV respectively.26 Despite the statistically significant difference
between treatment and control groups, researchers found that the incidence of PONV and need
for rescue anti-emetics in both treatment groups receiving dissimilar doses of haloperidol was
not significantly different.26 Primary findings from the Joo et al26 study demonstrated that the 1
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mg and 2 mg haloperidol doses were equally effective in preventing PONV when given in
conjunction with dexamethasone. According to the Joo et al26 publication, the combination of
dexamethasone with haloperidol was more effective in PONV prevention than dexamethasone as
a sole agent. Secondary findings showed that more sedation was observed in the group that
received 2 mg dose of haloperidol while other groups showed no significant difference.26 Three
subjects in group H2 also experienced hypotension, which was treated with ephedrine and not of
significant influence.26 All groups did not show a significant difference in pain severity and there
were no cardiac or neurologic adverse effects reported.26
Chaparro et al27 also evaluated the efficacy of haloperidol and dexamethasone in PONV
prophylaxis among 166 non-smoking women undergoing otorhinolaryngological or cosmetic
surgery in 2010. Inclusion criteria were an ASA score of I – II, age 18 – 50 years old, ambulatory
plastic/ otorhinolaryngological procedure, and female.27 Exclusion criteria were a history of EPS,
anti-emetic use within 24 hours of surgery, steroid use within 3 months of surgery, or
hypersensitivity to morphine, haloperidol, nonsteroidal anti-inflammatory drugs (NSAIDs), or
metoclopramide.27 The Chaparro et al27 study is considered level II evidence that has a quasiexperimental design since it uses a non-equivalent control group. Participants in the treatment
group of the Chaparro et al27 study were given 1.5 mg of IV haloperidol and 8 mg of IV
dexamethasone, which was compared to the placebo group that received 8 mg of IV
dexamethasone. All subjects participating were randomly assigned based on a computergenerated list and the hospital pharmacist facilitated the treatment allocation schedule.27 Besides
the hospital pharmacist, all providers involved in patient care were blinded to study groups,
which functioned as a method to reduce bias.27 Throughout the study, additional constants were
general anesthetic technique with the administration of midazolam, lidocaine, propofol,

34
remifentanil infusion, sevoflurane, and rocuronium, as well as analgesia provided by morphine
and diclofenac.27 Blinded evaluators observed patients postoperatively and recorded data at 30
minutes and 2 hours after which a telephone surgery was done at 6 and 24 hours following
surgery.27 Researchers primarily focused on determining the incidence of PONV; however, other
factors were also studied such as sedation level, adverse effects, and degree of pain.27 Data was
analyzed using STAT-XACT software in addition to t-tests, Mann-Whitney test, and Fisher’s
exact test.27 After 30 minutes and 2 hours, researchers did not find any significant difference
regarding PONV incidence among study groups and there was no difference regarding sedation
level and pain severity.27 A primary finding showed that there was no statistically significant
protective effect for nausea prevention observed with the combination therapy at 6 and 24 hours,
but the overall incidence of nausea was lower in the haloperidol with dexamethasone group at
22.5% and 41.5% respectively versus the dexamethasone group at 27.5% and 52.5%
respectively.27 The Chaparro et al27 publication underscores how the incidence of vomiting was
reduced at 6 hours and its decreased incidence became statistically significant at P < 0.05 at 24
hours with combination therapy. At 6 hours, patients who received the combination therapy
reported a lower incidence of vomiting at 15% versus dexamethasone alone at 26.25%.27 At 24
hours, patients who received haloperidol and dexamethasone experienced a lower incidence of
vomiting at 21.25% versus dexamethasone alone at 41.25%.27 Therefore, participants who
received dexamethasone without haloperidol experienced inferior PONV prophylaxis.26 Chaparro
et al27 reported no significant adverse effects, including EPS, in patients who received
haloperidol.
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Combined Effect of Haloperidol and Dexamethasone on PONV Versus Sole Use of
Haloperidol, Droperidol, or Dexamethasone
In 2008, Chu et al28 explored the combined PONV prevention power of haloperidol and
dexamethasone among 400 women undergoing laparoscopic-assisted vaginal hysterectomy.
Inclusion criteria were women of ASA class I – II scheduled for laparoscopic-assisted vaginal
hysterectomy.28 Exclusion criteria were anti-emetic use within 24 hours of the study, obesity,
(BMI greater than 35 kg/m2), difficult airway, major organ disease, or pregnancy.28 The Chu et
al28 study is considered an experimental study that has level I evidence due to the randomized
assignment of treatment groups and utilization of a traditional control group. Participants in the
Chu et al28 study were divided into the following groups that received: 2 mg of haloperidol with
5 mg of dexamethasone (group H + Dx), 5 mg of dexamethasone (group Dx), 2 mg of
haloperidol (group H), 1.25 mg of droperidol (group D), or saline (group S). A computergenerated random number table was used to randomly assign subjects to a treatment or control
group.28 The preparation of medications was performed by a nurse anesthetist who placed all
medications in identical syringes containing the medications diluted with saline to total a volume
of 2 mL.28 To reduce bias, all involved in patient care, patients, and investigators collecting
postoperative data were blinded to study groups with the exception of the nurse anesthetist
preparing medications.28 All patients were subjected to the same general anesthetic technique
with endotracheal intubation and mechanical ventilation that involved the following medications:
fentanyl, lidocaine, propofol, rocuronium, desflurane, oxygen, neostigmine, and atropine.28
Postoperatively, patients were observed for a total of 24 hours during which they were initially
observed for 2 hours in the PACU after which they were transferred to a ward.28 The foci of this
experiment centered on determining the severity and incidence of PONV, as well as the need for
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rescue anti-emetics.28 Other factors considered in this study were sedation level, severity of
postoperative pain, and the occurrence of treatment side effects such as EPS.28 Data was
analyzed using ANOVA, Bonferroni t-test, Kruskal-Wallis test, Mann-Whitney test, Chi-square
tests, and Fisher’s exact test.28 After 24 hours, researchers found no significant difference in
PONV incidence among groups that received droperidol, haloperidol, or dexamethasone;
however, when compared to the saline control group, the groups receiving anti-emetics showed
to have a lower incidence of PONV.28 More specifically, the statistically significant PONV
incidences at P < 0.05 between 0 – 24 hours were the following in respective groups: 19% with
haloperidol plus dexamethasone, 36% with droperidol, 37% with haloperidol, 38% with
dexamethasone, and 65% with saline. Additionally, there was no significant difference in the
occurrence of EPS, QTc interval changes, sedation, and pain intensity among all groups.28 The
primary finding in this randomized, double-blinded and positive-control study published that
patients who received the combination of 2 mg of haloperidol and 5 mg of dexamethasone
experienced superior PONV prophylaxis compared to other drugs utilized, which was
statistically significant at P < 0.05.28
Combined Effect of Dexamethasone and Haloperidol or Dexamethasone and Ondansetron on
PONV Versus Sole Use of Dexamethasone
In 2012, Wang et al29 conducted a study on PONV related to PCA on 135 female patients
undergoing gynecologic, abdominal, and orthopedic surgeries who were expected to receive
morphine PCA. Inclusion criteria for participation in this study were the following: an ASA
score of I – II, orthopedic surgery including knee/hip arthroplasty, colorectal abdominal surgery,
gynecologic surgery including total/modified hysterectomy, age of 18 – 65 years, and use of
morphine PCA.29 Exclusion criteria involved history of EPS, kidney/hepatic disease, gastric
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reflux, cardiac arrhythmia, and difficult intubation.29 Additionally, patients who had been treated
with anti-emetics within 24 hours of surgery were not included in the study.29 The randomized
allocation of subjects to three study groups was facilitated by a computer-generated system; D
group received 5 mg of IV dexamethasone, DH group received 2 mg of IM haloperidol 30
minutes within of the end of surgery along with 5 mg of IV dexamethasone at induction, and
group DO patients were given 4 mg of IV ondansetron 30 minutes within the end of surgery
along with 5 mg of IV dexamethasone at induction.29 The same general anesthesia technique was
performed on all subjects, which involved endotracheal intubation and administration of
fentanyl, propofol, rocuronium, sevoflurane, glycopyrrolate, neostigmine, and analgesia provided
by morphine PCA pump.29 Patients who needed rescue anti-emetics received 10 mg of IV
metoclopramide and 1 mg of IV ondansetron was given if PONV did not resolve.29 Researchers
aimed to diminish bias by blinding evaluators to the study groups; however, the anesthesiologist
was aware of the assignments.29 Overall, the study demonstrated a quasi-experimental design
with good, level II evidence due to the use of a non-equivalent control group and lack of a
traditional control group.29 Data in the Wang et al28 study was collected over a 24-hour
observation period that began 2 hours after surgery and then every 6 hours thereafter.29 The
primary focus of the study aimed to determine the incidence of PONV among different subject
groups, but researchers also took into consideration any adverse effects that resulted from each
of the medications, as well as sedation level and pain severity.29 Researchers utilized one-way
ANOVA, Bonferroni t test, Kruskal-Wallis test, Mann-Whitney ranked-sum test, Chi-square test,
Fischer’s exact tests to analyze data, which was processed using the 10.0 version of SPSS
software compatible with windows.29 As a result, researchers in the Wang et al28 study found no
significant difference among study groups regarding pain severity, sedation level, or adverse
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effects. It is important to note that subjects also did not experience any cardiac arrhythmias
throughout the study.29 When considering the incidence of PONV, subjects in the DO and DH
groups showed a significant difference at P < 0.05 when compared to group D.29 Both treatment
groups that received haloperidol or ondansetron in combination with dexamethasone experienced
diminished PONV incidence and there was less need for rescue anti-emetics over the course of
24 hours.29 Specifically, total PONV after 24 hours in group D was 25%, which was higher than
group DH at 15% and group DO at 13%.29 Therefore, participants in the Wang et al29 study
showed similar PONV prevention after receiving 5 mg of dexamethasone IV with 2 mg
haloperidol intramuscularly (IM) or the combination of 5 mg of dexamethasone IV and 4 mg of
ondansetron IV. After administration of 5 mg of dexamethasone IV with 2 mg haloperidol
intramuscularly (IM) or the combination of 5 mg of dexamethasone IV and 4 mg of ondansetron
IV dosages, there was not an increased incidence of sedation, EPS, or QT prolongation.29
Findings published by Wang et al29 also demonstrated that sole treatment of PONV with 5 mg of
dexamethasone IV was not as efficacious as combination therapy with haloperidol or
ondansetron.
Combined Effect of Haloperidol and Ondansetron on PONV Versus Sole Use of Ondansetron
Grecu et al30 published a randomized, double-blind trial in 2008 that compared the PONV
efficacy between combination therapy and a sole anti-emetic agent among 268 general anesthesia
or combined general anesthesia-epidural patients.30 Inclusion criteria were patients with an ASA
class of I – III who were 18 years of age or older that were undergoing general/combined
epidural-general anesthesia with a high risk for PONV.30 Exclusion criteria were patients with
history of seizures, Parkinson’s disease, cardiac dysrhythmias, prolonged QTc intervals greater
than 450 milliseconds (ms), and adverse reactions to ondansetron or haloperidol, as well as those
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who have undergone chronic treatment with dexamethasone or dopamine antagonists.30 The
Grecu et al30 study is considered to have a quasi-experimental design with level II evidence due
to the presence of a non-equivalent control group. Participants in the Grucu et al30 study were
randomly divided into two groups that received 1 mg of IV haloperidol and 4 mg of IV
ondansetron administered together to evaluate the effect of combination therapy, or 4 mg of IV
ondansetron administered alone used for comparison. Intraoperatively, all patients received 4 mg
of ondansetron along with the contents of a coded syringe that was randomly assigned 0.2 mL of
saline or 1 mg of haloperidol.30 Per the study, patients and investigators were blinded during the
randomization and collection of data process.30 Patients were observed for PONV in the PACU
every 30 minutes until discharged, after which a follow-up phone call was placed 480 minutes
after initial PACU admission to further evaluate the patient’s postoperative status.30 Not only
was the incidence of PONV studied, but investigators also focused on possible side effects, level
of sedation, and need for PONV rescue.30 Data was analyzed using single factor ANOVA,
student’s t-test, Kolmogorov–Smirnov test, Wilcoxon’s ranked sum test, chi-squared test,
Kaplan-Meier survival analysis, log rank test, and STATA 8.0 statistical software.30 Among
patients who received haloperidol and ondansetron the following findings were significant: 90%
with complete PONV response after 60 minutes, 76.2% complete PONV response after 480
minutes, 10% with nausea at 60 minutes or less, 23.9% with nausea at 480 minutes or less, 7.7%
needing rescue at 180 minutes or less, and 20.8% needing rescue at 480 minutes or less.30 In
comparison, among patients who only received ondansetron, the following findings were
significant: 66.2% with complete PONV response after 60 minutes, 59.2% with complete PONV
response after 480 minutes, 33.8% with nausea at 60 minutes or less, 42.3% with nausea at 480
minutes or less, 24.1% needing rescue at 180 minutes or less, and 37.6% needing rescue at 480
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minutes or less.30 The time to rescue in those who received haloperidol plus ondansetron was
154.4 + 133.8 minutes which was longer than ondansetron at 75.3 + 82.8 minutes.30 Overall, the
combination therapy with haloperidol and ondansetron provided a longer lasting and efficacious
PONV prophylaxis versus ondansetron without haloperidol that was statistically significant with
a P value < 0.001.30 Additionally, investigators found no significant difference among groups
regarding incidence of serious dysrhythmias, QTc prolongation, other toxicity, or sedation.30
Although there are limitations noted in the Grecu et al30 study regarding the lack of a
standardized surgical population and anesthetic, there are still valid findings found with use of
anti-emetics used in combination, which are applicable to PONV prophylaxis in anesthesia
practice.30
Combined Effect of Haloperidol and Ondansetron on PONV Versus Sole Use of Haloperidol
or Ondansetron
In 2009, Feng et al31 conducted a randomized double-blind study to determine PONV
prevention with haloperidol and ondansetron in 210 patients undergoing elective laparoscopic
cholecystectomy. Inclusion criteria were patients scheduled for laparoscopic cholecystectomy
who were classified as ASA I – II.31 Exclusion criteria were pregnancy, obesity (BMI > 35
kg/m2), psychiatric illness, difficult airway, significant major organ disease, anti-emetic drug use
within 24 hours of the study, and QTc interval greater than 440 ms.31 The Feng et al31 study is
considered a quasi-experimental study that has level II evidence due to the randomized
assignment of treatment groups and utilization of a non-equivalent control group. A computergenerated random number table was used to randomly assign subjects to a treatment or control
group.31 Participants in the Feng et al31study were divided into the following groups that
received: 2 mg of IM haloperidol with 2 mL of IV saline (group H), 4 mg of IV ondansetron with
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2 mL of IM saline (group O), or 2 mg of IM haloperidol with 4 mg of IV ondansetron (group H
+ O). IV test drugs were administered after induction and again re-dosed 30 minutes before
surgery was complete.31 Medications were prepared by a nurse anesthetist who labeled syringes
IM or IV, and investigators and patients were also blinded during randomization and data
collection to reduce bias.31 General anesthesia with endotracheal intubation and mechanical
ventilation was standardized in all patients who received lidocaine, fentanyl, propofol,
rocuronium, desflurane, oxygen, neostigmine, and atropine.31 Postoperatively, patients were
observed for a total of 24 hours during which they were initially observed for 2 hours in the
PACU after which they were transferred to a ward.31 The incidence and severity of PONV was
primarily studied during this experiment along with the need for rescue anti-emetics.31
Additionally, the severity of postoperative pain and the occurrence of treatment side effects such
as EPS, sedation and prolonged QTc interval, were also studied.31 Data was analyzed using
ANOVA, Tukey’s Honestly Significance Difference test, Kruskal-Wallis test, Mann-Whitney
test rank sum test, Chi-square tests, and Fisher’s exact test.31 Researchers in the Feng et al31 study
administered 4 mg of IV ondansetron and 2 mg of IM haloperidol versus each drug alone and
found that the combination treatment of haloperidol and ondansetron yielded a greater PONV
prevention response and an increase in patient satisfaction. The total PONV incidence among
patients who received haloperidol plus ondansetron was 21% at 0 – 24 hours; however, there was
39% at 0 – 24 hours for those who only received haloperidol and 38% at 0 – 24 hours for those
who only received ondansetron.31 Just as important, the complete PONV response was 79% in
the group that received haloperidol plus ondansetron; yet, 62% and 61% in subjects who
received ondansetron and haloperidol respectively.31 Patients who received haloperidol plus
ondansetron had a higher satisfaction score of 8.3 + 1.8 when compared to ondansetron with 7.2
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+ 2.5 and haloperidol with 7.0 + 2.4.31 After 24 hours, there was no significant difference in the
incidence of PONV and need for rescue analgesics among groups that only received haloperidol
or ondansetron (P < 0.05).31 There was also no significant difference in QTc prolongation,
incidence of EPS, and sedation level among all groups.31 Of significant importance was that
subjects who received both haloperidol and ondansetron suffered the lowest incidence of PONV
and required less rescue analgesics or anti-emetics.31 Thus, findings in the Feng et al31 study
point to a statistically significant superior PONV prophylaxis with combination therapy
involving haloperidol plus ondansetron at P < 0.05.
Summary of the Evidence
The most current research centers around adult surgical patients undergoing general
anesthesia who have received PONV prophylactic treatment. The literature mainly points to
documenting the incidence of PONV during the perioperative period despite anti-emetic
treatment in laparoscopic hysterectomy, laparoscopic cholecystectomy, laparoscopic sleeve
gastrectomy, laparoscopic gynecological, orthopedic, abdominal, cosmetic, and
otorhinolaryngological surgery patients. All articles discussed haloperidol administration in
combination PONV treatment except for Dağ et al32 that studied haloperidol’s efficacy as a sole
agent. The anti-emetics used with haloperidol varied slightly; one study, Benevides et al,25
administered haloperidol with dexamethasone and ondansetron, while four studies analyzed the
efficacy of haloperidol with dexamethasone and two studies focused on the efficacy of
haloperidol with ondansetron.
The selected publications that studied PONV prophylaxis with haloperidol focused on the
PONV incidence with opioid analgesia administered in two different ways. Two research groups,
Dağ et al32 and Wang et al29 utilized PCA opioid analgesia postoperatively, while five studies
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Benevides et al,25 Joo et al,26 Chaparro et al,27 Chu et al,28 Feng et al31 aimed for narcotic pain
management administered by anesthesia providers avoiding PCA. All study subjects only
received fentanyl during induction to facilitate tracheal intubation except for those in the Joo et
al26 and Chaparro et al27 studies who received a remifentanil infusion and Benevides et al25
subjects who received both fentanyl for induction and a remifentanil infusion during
maintenance. One study, Grecu et al,30 did not specify the type or method of narcotic used during
general anesthesia. All studies except for three, Benevides et al,25 Grecu et al,30 and Feng et al31
used females as subjects, which provided a representation of the overall population.
In general, all studies showed a decreased incidence of postoperative vomiting when
haloperidol was administered in combination with other anti-emetics, dexamethasone and
ondansetron, or haloperidol used alone. More than 85% of literature selected showed that
haloperidol provided a protective effect against postoperative nausea when used in combination
treatment and as a sole agent. Additionally, all subjects receiving haloperidol for PONV
prophylaxis, in combination therapy or alone, did not exhibit significant adverse effects,
increased sedation level, or a greater pain medication requirement.
Conclusion
Research demonstrates that PONV negatively affects surgical patients despite the use of
available anti-emetic treatments. According to the algorithm published by the British Journal of
Anesthesia and the guidelines suggested by the International Anesthesia Research Society, which
is supported by the ASA and AANA, combination PONV prophylaxis is modeled as a goal of
perioperative care.8-9 Within the International Anesthesia Research Society’s guidelines,
haloperidol is featured as a prophylactic anti-emetic that showcases its reasonable capacity for
inclusion in anesthesia practice.8
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Rationale
Although the literature presented is valid and significant, diminished adherence to
combination PONV prophylaxis recommendations, especially with haloperidol, has been noted
as an issue in current practice.8-9 This dissemination brings to light the promising potential of
haloperidol in different surgical settings and various treatment types, which can be appealing for
anesthesia providers who share the goal of optimal PONV prophylaxis. If the presentation of this
inclusive research positively influences anesthesia provider attitudes and increases knowledge
respectively, there is the possibility for its application in current anesthesia practice to diminish
the incidence of PONV as evidenced by the analyzed literature.
Objectives
DNP Project Goals
PONV is considered a common postoperative adverse event that warrants prevention.8-9
Although different anti-emetics have been utilized in practice with effects on various PONV
associated receptors, patients continue to suffer from poor outcomes.8-9 Negative outcomes
reported include delayed hospital discharge, poor patient satisfaction, increased costs, and
complications such as aspiration, airway compromise, electrolyte disturbances, bleeding,
dehydration, wound dehiscence, ruptured esophagus, and limited oral intake.1,5,11,14 According to
the International Anesthesia Research Society and the British Journal of Anesthesia, current
recommendations point to the use of combination medication therapy for PONV prophylaxis,
which shows significant promise in diminishing the debilitating outcomes associated with poor
PONV prevention compared to the use of anti-emetics as sole agents.8-9
Among the research gathered and reviewed, haloperidol has been showcased as an
efficacious PONV prophylactic medication; however, its use is not consistent despite the
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suggestion of butyrophenones in current algorithms.9 It is hypothesized that the decreased use of
haloperidol can be attributed to a lack of knowledge regarding its value.9 The primary goal of
improving anesthesia provider knowledge and attitude is to show the benefit of incorporating
haloperidol in adult PONV prophylaxis to complement the guidelines proposed by the
International Anesthesia Research Society. The objective of this Quality Improvement Project is
to improve anesthesia provider knowledge and attitudes regarding haloperidol’s efficacy in
preventing PONV which can set the foundation for the application of evidence-based practice for
PONV prophylaxis.
SMART Goals and Outcomes
In efforts to formulate goal objectives, the SMART framework was implemented. The
SMART framework entails utilizing objectives that are specific, measurable, achievable,
realistic, and timely.33
Specific
Anesthesia providers will have an education module on the utilization of haloperidol as a
pharmacological complement for PONV prophylaxis in adult surgical patients.
Measurable
The value of the educational module will be gauged through pre and post questionnaires
that assess anesthesia provider knowledge and attitudes prior to participation and after the
PowerPoint educational module. Measurement of outcomes will be realized before and after
intervention taking into consideration the variation in anesthesia provider feedback in respect to
knowledge of the use of haloperidol as an anti-emetic, combination PONV therapy, and PONV.
Qualtrics will provide the software to streamline surveys and facilitate a compilation of data with
respective analysis.
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Achievable
Certified Registered Nurse Anesthetists (CRNAs), Anesthesiologists, and Anesthesia
Assistants (AAs) in affiliated hospital systems will provide a sufficient sample size to generate
findings indicating whether learning has occurred in respect to the PONV prophylaxis potential
of haloperidol, especially in combination therapy. Additionally, findings will also provide insight
into whether anesthesia provider attitudes towards haloperidol use in practice reflect a positive or
negative outlook.
Realistic
Anesthesia providers will be educated on the suggested utilization of haloperidol for
PONV prophylaxis in adult surgical patients along with commonly administered anti-emetics
used in combination. Multi-media presentation will provide the primary avenue of highlighting a
PONV algorithm.
Timely
Over the course of eight months, the primary investigator will collect data, analyze
findings, and disseminate statistically significant results. Anesthesia providers will be allotted a
four-week time-period to participate in the QI project. Pertinent outcomes of this QI project will
showcase the quality of the educational module taught that focuses on the efficacy of haloperidol
as a pharmacological complement in PONV prophylaxis, and the receptivity of CRNAs, AAs,
and anesthesiologists to apply findings in practice that are centered around utilizing combination
therapy.
Program Structure
The success of this educational module in improving knowledge and attitudes among
anesthesia providers depends on the support of all stakeholders. Vital stakeholders are identified
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as participants and care providers who aim to facilitate a practice change that involves promoting
the use of haloperidol as a pharmacological complement in PONV prophylaxis. The aforesaid is
realized through mobilizing the anesthesia community to influence perioperative practice, which
parallels appreciating the associated positive outcomes of haloperidol use in PONV prophylaxis.
Through a pre-intervention questionnaire, participants’ baseline knowledge and attitudes can be
assessed regarding PONV, haloperidol’s role in PONV prophylaxis, PONV management, and the
negative outcomes associated with PONV. An educational module provided to anesthesia
providers will model the benefits of haloperidol use in PONV prophylaxis and highlight the role
of its medication class in currently recommended PONV guidelines. The presentation of this
educational module and surveying of participants can be facilitated by hospital system electronic
mail and inclusion of in-services per approval of hospital institutional review board regulations.
Following the exhibition of the educational module, participants will complete a post survey to
evaluate learning. A strengths, weaknesses, opportunities, and threats (SWOT) analysis is
instrumental in understanding the essential variables that influence and guide the development of
this QI project.34 In comprehending and addressing the SWOT analysis variables, buttressing
weaknesses can initiate project strengths and detection of threats can birth opportunities.34
SWOT Analysis
Strengths and Opportunities
According to Helms and Nixon,34 opportunities coincide strongly with the strengths of
any venture that involves strategic management. Strengths in a SWOT analysis delineate what
factors are present that promote the appreciation of opportunities.34 Implementation of PONV
prophylaxis algorithms in anesthesia practice encourage the use of combination anti-emetic
therapy, which has been tied to improved postoperative patient outcomes highlighting a crucial
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strength.8-9 It is anticipated that incorporation of haloperidol in current PONV practice can
enhance the recovery process of patients underscoring a pivotal opportunity.20,25-32 The
collaboration of motivated anesthesia providers inspired to transform the postoperative
experience can begin with access to learning the opportunities present to induce an evolution of
perioperative practice patterns.35 To make this possible, recruitment of anesthesia providers to
participate and endorse the paradigm shift to diminish PONV is necessary. While anesthesia
providers are the primary stakeholders in this QI project, the aspired outcome of improving
knowledge and attitudes of PONV provides additional opportunities for the involvement of
supplemental stakeholders such as patients and post anesthesia care unit (PACU) nursing staff.35
Through the dissemination and publication of this QI project’s findings, there is room for an
increased demand for patient-centered care that includes patient shared decision-making, as well
as the participation of medical staff essential in the care and recovery of adult surgical patients.3536

The aforesaid factors reinforce the potential success of this QI project and may promote the

coexisting goal of compliance and practice change among anesthesia providers that considers
haloperidol use for PONV combination therapy.35
Weaknesses and Threats
Helms and Nixon34 also identify that any program’s weaknesses can delay progress and
amplify threats. Unfavorable internal and external issues can underscore weaknesses and act as
project failure catalysts that can hinder overcoming the risk of a persistent threat to project
implementation.34 Anesthesia providers’ dearth of knowledge regarding the studied topic can be
a primary weakness in promoting practice change.35 Failure to adhere to guidelines suggested for
PONV prophylaxis can also pose as a threat to long-term compliance in practice and propagation
of available PONV knowledge.9 Additionally, variations in anesthesia provider training, beliefs
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about medication efficacy/side-effects, and judgement can be classified as threats.37 Therefore,
anesthesia provider bias regarding PONV prophylaxis can be detrimental and threatens the
development of this QI project.
Organizational Factors
The implementation of a PONV prophylaxis education module that highlights the value
of haloperidol in combination PONV therapy serves as an opportunity to combat threats to
perioperative practice change and QI project development. Utilization of diagrams that correlate
with the applicable literature facilitate a visual depiction of the suggested PONV algorithm that
includes haloperidol. Sufficient sponsorship with an anesthesia team that shares the same
objective as the surveyor is critical for the support of this PONV educational module. The
participating anesthesia team can provide a reservoir of information critical to evaluating the
efficacy of the educational module presented. Data analysis can provide a report of knowledge
deficit present and highlight learning that occurred among participating anesthesia providers.
Understanding data, studying how findings align with QI project goals, and providing a
corresponding dissemination are vital to evaluating the educational module. Dissemination
components include background information, PICO question, methods, results, data analysis
process, conclusions, limitations, and opportunities for improvement.
Conceptual Underpinning and Theoretical Framework
A theoretical framework integrated into research provides a structure that guides the
study and highlights a rationale for suggested practice.38 The middle-range nursing theory that
will be used to guide the development of this QI project is the Theory of Unpleasant Symptoms
(TOUS).38-39 While patients commonly suffer from PONV, there are other postoperative
outcomes that can occur simultaneously, such as pain, bleeding, venous hypertension,
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esophageal rupture, wound dehiscence, decreased oral intake, electrolyte disturbances,
dehydration, and airway compromise.1,5,11,14 The TOUS allows for the consideration of multiple
symptoms that can interact with each other and affect patient outcomes postoperatively; this
provides a realistic representation of the perioperative process.38-39 This theory models how
symptoms can act synergistically when presenting together and how control of one symptom can
assist with the management of others.38 In providing anesthesia providers with updated valuable
knowledge through the implementation of a PONV educational module, the management of the
unpleasant symptoms of PONV can be further understood.39 By employing suggested evidencebased practice promoted in the PONV educational module, there is the potential for anesthesia
providers to diminish the incidence of PONV with the use of haloperidol and combination antiemetic therapy.39 In application of the TOUS, it is hypothesized that addressing PONV may
assist with management of other postoperative symptoms that afflict patients.38
Methodology
Setting and Participants
This DNP project will take place at Memorial Regional Hospital located in Hollywood,
Florida. The primary project participants will be the anesthesia providers. The participants will
be recruited voluntarily via email and the anticipated sample size will be between 4 – 10
participants.
Description of Approach and Project Procedures
The primary methodology of the proposed project is to administer an online educational
module to anesthesia providers that focuses on the significance of PONV in anesthesia practice
and the impact of combination PONV prophylaxis utilizing haloperidol. All phases of the
educational module can be completed with the use of a computer, tablet, or smartphone. The
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project will be implemented in the first phase by conducting an online pre-test that will gauge
baseline knowledge and attitudes on the subject. The second phase will be comprised of a
PowerPoint presentation as the primary means of learning that includes important information
regarding PONV, PONV prophylaxis, and the role of haloperidol and other anti-emetic agents in
anesthesia practice. The third phase of the project will involve a post-test to evaluate knowledge
gained and any changes in anesthesia provider attitudes about the subject presented. The results
will provide feedback regarding the impact of the educational intervention and how the proposed
PONV prophylaxis clinical recommendations influence anesthesia provider attitudes.
Protection of Human Subjects
Initial project approval by the Institutional Review Board (IRB) of Florida International
University (FIU) is a prerequisite for the launch of the educational module. For this QI project,
the recruitment population will include anesthesia providers who work at Memorial Regional
Hospital and are involved in anesthesia practice. Recruitment activities will be conducted via
email with the invitation indicating voluntary participation without penalty for withdrawing from
the QI project. Participating anesthesia providers will benefit from an increase in knowledge and
improvement in attitude about utilizing haloperidol as a pharmacological complement for PONV
prophylaxis in adult surgical patients. The main risks for this quality improvement project are
minimal. As with any educational module, potential minimal risks are mild emotional stress or
physical discomfort from sitting on a chair for an extended period of time.
Data Collection
In this project, the primary tools that will be utilized to evaluate the effectiveness of the
intervention are a pre-test and post-test that follow a survey format. Qualtrics will be used to
implement both 16-question surveys that inquire about knowledge of PONV, haloperidol, and
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PONV prophylaxis using combination therapy. Participants will also be asked to express
attitudes regarding the inclination to implement haloperidol into anesthesia practice and the
administration of haloperidol as a complementary drug to decrease PONV. Other collected data
include the following: participant gender, age, ethnicity, level of education, and years of
experience. The pre-test survey will provide an evaluation of baseline knowledge on the subject
and identify any knowledge gaps that would warrant the implementation of the educational
module. The post-test survey will reveal if participants learned from the educational module and
are willing to incorporate what was learned into anesthesia practice. The data collected will be
confidential and no subject identifiers will be recorded during any component of the QI project.
Data Management and Analysis Plan
The primary investigator for the project will be the DNP student who will be
implementing the surveys. All data collected will be stored in a password protected database
accessible by the primary investigator and DNP project supervisor. There will be no record of
participant personal identifiers to protect confidentiality. The efficacy of the intervention will be
measured by comparing the pre-test answers to those of the post-test with the assistance of
statistical analysis.
Results
Pre-Test Demographics
The pre-test demographics are displayed in Table 1, shown below.
Table 1. Pre-Test Participant Demographics
Demographic
Total Participants
Age

n (%)
6 (100.00%)
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25-34
35-44
45-54
55-64
65+

3 (50.00%)
0 (0.00%)
3 (50.00%)
0 (0.00%)
0 (0.00%)

Gender
Male
Female

2 (33.33%)
4 (66.67%)

Ethnicity
African American
Caucasian
Hispanic
Other

1 (16.67%)
2 (33.33%)
2 (33.33%)
1 (16.67%)

Medical Profession
CRNA
AA
Anesthesiologist
Other

6 (100.00%)
0 (0.00%)
0 (0.00%)
0 (0.00%)

Highest Education
Associate’s degree
Bachelor’s degree
Master’s degree
Doctoral degree
Experience
Less than 1 year
1 to 5 years
6 to 10 years
More than 10 years

0 (0.00%)
0 (0.00%)
0 (0.00%)
6 (100.00%)

2 (33.33%)
1 (16.67%)
0 (0.00%)
3 (50.00%)

There were six participants in the pre-test demographics, and all completed the pre-test
survey. Most of the participants were female (n=4, 66.67%), as opposed to male (n=2, 33.33%).
There were also a range of ethnicities represented: African American (n=1, 16.67%), Caucasian
(n=2, 33.33%), Hispanic (n=2, 33.33%), and other (n=1, 16.67%). Information was obtained
regarding the participant’s role at the hospital, and it was found that all participants were
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Certified Registered Nurse Anesthetists (CRNAs) (n=6, 100%). The participants were questioned
about the length of time practicing, finding that the practice period ranged: less than one year
(n=2, 33.33%), 1 to 5 years (n=1, 16.67%), 6 to 10 years (n=0, 0%), and more than 10 years
(n=3, 50.00%).
Pre-Test PONV Knowledge
Pre-test knowledge on PONV showed that two participants (33.33%) were aware that the
incidence of PONV can be as high as 80%. Therefore, a majority of participants (66.67%) were
unaware of the clinical incidence of PONV. When asked to select the unpleasant symptoms
associated with PONV contributing to considerable patient morbidity and distress, three
participants (50.00%) selected the correct answer that included esophageal rupture, wound
dehiscence, aspiration, and dehydration.
Pre-Test Haloperidol PONV Prophylaxis Knowledge
Before the educational intervention, half of the participants (n=3, 50.0%) knew that the
most efficacious parenteral dose range of haloperidol for PONV prophylaxis is 0.5 – 2 mg. Most
participants (n=4, 66.67%) knew that haloperidol is classified as a dopamine D2 receptor
antagonist. When asked to select all of haloperidol’s mechanisms of action that contribute to its
clinical effects, the correct answer was selected once (12.5%), and seven of the eight answers
chosen were incorrect (87.5%). Three participants (50.00%) knew what population of surgical
patients would benefit from PONV prophylaxis with haloperidol, which are patients undergoing
otorhinolaryngological, ophthalmic, laparoscopic, and gynecological procedures. When asked to
select all of the disease processes (Parkinson’s disease, neuroleptic malignant syndrome,
acute/chronic dysrhythmias, and QT prolongation) that should preclude the use of haloperidol,
the correct answer was selected three times (42.86%) and four of the seven answers chosen were
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incorrect (57.14%). When asked to select two potential side effects of haloperidol at high doses,
such as 35 mg or more, the majority of answers chosen (n=9, 75%) were correct. When asked to
identify what two other medications have shown superior PONV prophylaxis when used in
combination with haloperidol, most answers (n=7, 58.33%) selected were correct and identified
dexamethasone and ondansetron. Only one participant (16.67%) knew that PONV prophylaxis is
most efficacious when haloperidol is administered at any time intraoperatively. Half of the
participants (50.00%) knew that haloperidol’s onset of action for PONV prophylaxis is 30
minutes, two participants (33.33%) knew that haloperidol’s duration of action for PONV
prophylaxis is 4 hours, and one participant (16.67%) knew that haloperidol’s elimination half-life
is 12 – 35 hours.
Pre-Test Utilization and Attitudes of Haloperidol PONV Prophylaxis
The inclination to implement haloperidol into anesthesia practice prior to the educational
module was low. Three participants (50.00%) were unsure, and one participant (16.67%) was
very unlikely to use haloperidol. Only two participants (33.33%) were likely to use haloperidol
in anesthesia practice. When asked how likely they were to administer haloperidol in
combination therapy for PONV prophylaxis, two participants (33.33%) were somewhat likely,
while two participants (33.33%) were somewhat unlikely, and two participants (33.33%) were
most unlikely. Therefore, a majority of participants (n=4, 66.66%) were unlikely to use
haloperidol in combination therapy for PONV prophylaxis. Attitudes toward the administration
of haloperidol as a complementary drug to decrease PONV were divided: one participant
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(16.67%) was very positive, two participants (33.33%) were positive, two participants (33.33%)
were neutral, and one participant (16.67%) was very negative.
Post-Test Demographics
Table 2 (see below) shows the post-test demographics.
Table 2. Post-Test Participant Demographics
Demographic
Total Participants

n (%)
5 (100.00%)

Age
25-34
35-44
45-54
55-64
65+

3 (60.00%)
0 (0.00%)
2 (40.00%)
0 (0.00%)
0 (0.00%)

Gender
Male
Female

1 (20.00%)
4 (80.00%)

Ethnicity
African American
Caucasian
Hispanic
Other

1 (20.00%)
2 (40.00%)
1 (20.00%)
1 (20.00%)

Medical Profession
CRNA
AA
Anesthesiologist
Other

5 (100.00%)
0 (0.00%)
0 (0.00%)
0 (0.00%)

Highest Education
Associate’s degree
Bachelor’s degree
Master’s degree
Doctoral degree
Experience

0 (0.00%)
0 (0.00%)
0 (0.00%)
5 (100.00%)
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Less than 1 year
1 to 5 years
6 to 10 years
More than 10 years

2 (40.00%)
1 (20.00%)
0 (0.00%)
2 (40.00%)

There were five participants in the post-test demographics, and all completed the survey.
Most of the participants were female (n=4, 80.00%), as opposed to male (n=1, 20.00%). There
were also a range of ethnicities represented: African American (n=1, 20.00%), Caucasian (n=2,
40.00%), Hispanic (n=1, 20.00%), and other (n=1, 20.00%). Information was obtained regarding
the participant’s role at the hospital, and it was found that all participants were Certified
Registered Nurse Anesthetists (CRNAs) (n=5, 100%). The participants were questioned about
the length of time practicing, finding that the practice period ranged: less than one year (n=2,
40.00%), 1 to 5 years (n=1, 20.00%), 6 to 10 years (n=0, 0%), and more than 10 years (n=2,
40.00%). It is noted that while there were fewer people completing the post-test survey, the
distribution of the sample was similar across both pre- and post-tests.
Post-Test PONV Knowledge
After the educational module, anesthesia provider knowledge on PONV improved. A
majority of participants (n=3, 60.00%) were aware that the incidence of PONV can be as high as
80%. Therefore, a minority of participants (n=2, 40.00%) were unaware of the clinical incidence
of PONV. When asked to select the unpleasant symptoms associated with PONV contributing to
considerable patient morbidity and distress, the correct answer that included esophageal rupture,
wound dehiscence, aspiration, and dehydration was selected by four participants (66.67%), while
incorrect answers were chosen by one participant (33.33%). There was a PONV knowledge
improvement noted for all questions. Table 3 shows the differences in responses from the pre- to
post-test.
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Table 3. PONV Knowledge Pre- and Post-Test
Question

The incidence of postoperative nausea
and vomiting can be as high as:
What are unpleasant symptoms
associated with PONV contributing to
considerable patient morbidity and
distress? (Select all that apply)

Correct in
Pre-test

Correct in
Post-test

Difference

33.33%

60.00%

26.67%

50.00%

66.67%

16.67%

Post-Test Haloperidol PONV Prophylaxis Knowledge
Anesthesia provider knowledge on haloperidol for PONV prophylaxis improved overall
after the educational module. All participants (n=5, 100.0%) knew that the most efficacious
parenteral dose range of haloperidol for PONV prophylaxis is 0.5 – 2 mg. Most participants
(n=3, 60.00%) knew that haloperidol is classified as a dopamine D2 receptor antagonist. When
asked to select all of haloperidol’s mechanisms of action that contribute to its clinical effects, the
correct answer was selected three times (42.86%) and four of the seven answers chosen were
incorrect (57.16%). When asked what population of surgical patients would benefit from PONV
prophylaxis with haloperidol, the correct answer was chosen three times (42.86%) and four of
the seven answers chosen were incorrect (57.16%). When asked to select all of the disease
processes that should preclude the use of haloperidol, the correct answer was selected three times
(42.86%) and four of the seven answer combinations chosen were incorrect (57.16%). When
asked to select two potential side effects of haloperidol at high doses, such as 35 mg or more, the
majority of answers (n=8, 80%) were correct. When asked to identify what two other
medications have shown superior PONV prophylaxis when used in combination with
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haloperidol, most answers (n=8, 80.00%) selected were correct and identified dexamethasone
and ondansetron. Two participants (40.00%) knew that PONV prophylaxis is most efficacious
when haloperidol is administered at any time intraoperatively. Four participants (80.00%) knew
that haloperidol’s onset of action for PONV prophylaxis is 30 minutes, four participants
(80.00%) knew that haloperidol’s duration of action for PONV prophylaxis is 4 hours, and three
participants (60.00%) knew that haloperidol’s elimination half-life is 12 – 35 hours. There was a
knowledge improvement noted in a majority of questions regarding haloperidol for PONV
prophylaxis. Table 4 shows the differences in responses from the pre- to post-test.
Table 4. Haloperidol PONV Prophylaxis Knowledge Pre- and Post-Test
Question

Correct in
Pre-test

Correct in
Post-test

Difference

50.00%

100.00%

50.00%

What classification of anti-emetic is haloperidol
considered?

66.67%

60.00%

- 6.67%

Haloperidol’s clinical effects can be attributed to
what mechanism(s) of action? (Select all that apply)

12.5%

42.86%

30.36%

50.00%

42.86%

- 7.14

42.86%

42.86%

0.00%

75.00%

80.00%

5.00%

What is the most efficacious parenteral dose of
haloperidol for PONV prophylaxis according to most
recent literature?

What population of surgical patients can benefit
from PONV prophylaxis with haloperidol? (Select
all that apply)
Haloperidol should be excluded from patients
presenting with which disease process(es) or
conditions? (Select all that apply)
Potential side effects of haloperidol at
high doses, such as 35 mg or more,
include (Select 2)
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Utilization of haloperidol in combination with what
other medications have shown superior PONV
prophylaxis? (Select 2)

58.33%

80.00%

21.67%

PONV prophylaxis is most efficacious when
haloperidol is administered when intraoperatively?

16.67%

40.00%

23.33%

What is haloperidol’s onset of action for PONV
prophylaxis?

50.00%

80.00%

30.00%

What is haloperidol’s duration of action for PONV
prophylaxis?

33.33%

80.00%

46.67%

16.67%

60.00%

43.33%

What is haloperidol’s elimination half-life?

Post-Test Utilization and Attitudes of Haloperidol PONV Prophylaxis
The inclination to implement haloperidol into anesthesia practice was high after the
educational module intervention. One participant (20.00%) was very likely, and four participants
(80.00%) were likely to implement haloperidol into anesthesia practice. When asked how likely
they were to administer haloperidol in combination therapy for PONV prophylaxis, one
participant (20.00%) was most likely, while four participants (80.00%) were somewhat likely.
Therefore, all participants (n=5, 100.00%) were more inclined to use haloperidol in combination
therapy for PONV prophylaxis and in anesthesia practice after the educational module. Attitudes
toward the administration of haloperidol as a complementary drug to decrease PONV were
improved: two participants (40.00%) were very positive, one participant (20.00%) was positive,
and two participants (40.00%) were neutral. There were no negative or very negative attitudes
expressed regarding haloperidol use in complementary PONV prophylaxis after the educational
module. Table 5 shows the differences in responses from the pre- to post-test.
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Table 5. Utilization and Attitudes of Haloperidol PONV Prophylaxis Pre- and Post-Test
Question

Pre-test

Post-test

Difference

How likely are you to implement haloperidol into
your anesthesia practice?
Very likely
Likely
Unsure
Unlikely
Very unlikely

0.00%
33.33%
50.00%
0.00%
16.67%

20.00%
80.00%
0.00%
0.00%
0.00%

20.00%
46.67%
- 50.00%
0.00%
- 16.67%

0.00%
33.33%
33.33%
33.33%

20.00%
80.00%
0.00%
0.00%

20.00%
46.67%
-33.33%
-33.33%

16.67%
33.33%
33.33%
0.00%
16.67%

40.00%
20.00%
40.00%
0.00%
0.00%

23.33%
- 13.33%
6.67%
0.00%
- 16.67%

How likely are you to administer haloperidol in
combination therapy for PONV prophylaxis?
Most likely
Somewhat likely
Somewhat unlikely
Most unlikely
What is your attitude toward the administration of
haloperidol as a complementary drug to decrease
PONV?
Very positive
Positive
Neutral
Negative
Very negative

Discussion
Limitations
In this QI project, there were limitations noted, small sample size was a limitation despite
the large number of potential participants invited to participate. Although there were thirty-seven
anesthesia providers from Memorial Regional Hospital invited to participate, six CRNAs
completed the pre-test, and only five CRNAs completed the post-test. After the educational
module was launched, anesthesia providers were reminded once via email to participate, and the
window to participate was one month long. The online modality of the educational module also
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contributed to this QI project’s limitations since the project was asynchronous and completed
entirely online. While the educational module delivery method posed as a barrier to presenting
the material to more providers, this QI project would have benefited from a live presentation
format in efforts to improve recruitment. Another limitation of this QI project was the inclusion
of one hospital facility. Potential factors to mitigate limitations are to address issues with
recruitment, allow for expansion of participation to other sites, and extend the time period to
participate.
Summary
The results show that there was a statistical difference between the pre-and post-tests.
The average amount of correct answers in the PONV knowledge pre-test were 41.67%, and an
average of 63.34% correct answers were noted in the post-test. The average amount of correct
answers in the haloperidol PONV prophylaxis knowledge pre-test was 42.91%, and an average
of 64.42% correct answers were reflected in the post-test. Therefore, a significant improvement
in knowledge regarding PONV and haloperidol PONV prophylaxis was observed in all
respondents with a 52.00% percent change and 50.13% percent change identified respectively.
The average amount of anesthesia providers inclined to utilize haloperidol in anesthesia practice
and for PONV prophylaxis were 33.33% in the pre-test, and 100.00% in the post-test. Overall,
there was an increase in the inclination to utilize haloperidol in anesthesia practice and for
PONV prophylaxis with a 200.03% percent change observed. The mean number of positive
answers observed in the pre-test surveying attitudes regarding haloperidol use for PONV
prophylaxis were 10.00%, and 12.00% in the post-test. There was also a significant improvement
in attitudes observed in all respondents regarding haloperidol use for PONV prophylaxis with a
20.00% percent change. The following figure demonstrates the aforementioned findings.
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Figure 7. QI Project Results

QI Project Results
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Future Implications for Advanced Nursing Practice
The implementation of the educational module can function as a segue in anesthesia
practice change. By showcasing literature on PONV and haloperidol PONV prophylaxis, the
information available to anesthesia providers can influence the inclination to use haloperidol in
anesthesia practice and as a complement drug with other anti-emetics for PONV prophylaxis.
The impact of the intervention is vital because it’s educational efficacy and ability to influence
the attitudes of anesthesia providers regarding haloperidol use, can affect adult surgical patient
outcomes. The data showed that the QI project was successful in increasing anesthesia providers’
knowledge and attitudes. The findings appreciated in this QI project can trigger further research
considering haloperidol and PONV prophylaxis. Despite the value of current literature, there is a
need for further research on haloperidol’s role in other clinical settings, such as when
implementing an anesthesia plan that involves multimodal analgesia.
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Conclusions
The results of this QI project offered valuable insight about how anesthesia provider
knowledge and attitudes are affected by an educational module considering haloperidol in
combination PONV prophylaxis. The findings assumed a positive relationship; anesthesia
provider knowledge on haloperidol and PONV prophylaxis increased, inclination to utilize
haloperidol in practice and for PONV prophylaxis increased, and overall attitudes improved.
Ultimately, this QI project was able to respond to the following research question: (P) In adult
surgical patients (I) does an educational module on the utilization of haloperidol as a
pharmacological complement for PONV prophylaxis (C) versus no educational module (O)
increase anesthesia provider knowledge and attitude in implementing haloperidol as an adjunct
treatment in the management of PONV?
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Appendix
Appendix A: Summary of the Literature Table
Author(s)

Benevides et
al,25
(2013)

Purpose

To investigate
and compare the
PONV
prophylaxis
efficacy of anti emetics used in
combination and
as sole agents.

Methodology
/ Research
Design
Randomized
doubleblinded study.
Quasiexperimental
Level II

Intervention(s)/
Measures

Sampling/Setting

Primary Results

Relevant
Conclusions

Randomized
double-blinded
study conducted
evaluating PONV
prophylaxis using
the combination of
haloperidol,
ondansetron, and
dexamethasone
compared to the
sole use of
ondansetron or
dexamethasone
with
ondansetron.24

Male and female
patients at least 18
years old
undergoing general
anesthesia for
laparoscopic sleeve
gastrectomy with
an ASA
classification of I –
III and BMI > 35
kg/m2.24

Patients who received
haloperidol, dexamethasone,
and ondansetron experienced
less nausea at 23.7% after 0
– 2 hours and 53.3% after 0
– 36 hours postoperatively
compared to patients who
only received ondansetron
and experienced nausea
56.7% after 0 – 2 hours and
86.7% after 0 – 36 hours,
with a P = 0.016 and P =
0.015 at each of the time
periods, respectively.24 There
was a statistically significant
difference of P = 0.015 in
the incidence of vomiting at
0 – 36 hours postoperatively
between the ondansetron
group with 53.3% and the
haloperidol, dexamethasone,
ondansetron group with
20%24

Lower PONV
incidence and the use
of rescue anti-emetics
was reduced in
groups that utilized a
combined PONV
treatment approach
including haloperidol,
ondansetron, and
dexamethasone.24

Sample size
n= 90
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Joo et al,26
(2015)

To investigate
haloperidol’s
efficacy in
PONV
prophylaxis as
an agent in
combination
therapy and
identify
haloperidol’s
most efficacious
dose.25

Randomized
doubleblinded dose
response and
placebocontrolled
study.
Experimental
study

Randomized
double-blinded
study conducted
evaluating PONV
prophylaxis using
the combination of
haloperidol and
dexamethasone
compared to
dexamethasone
alone.25

Female patients
between ages 20 –
65 years old with
ASA classification
I – II, non-smoking
status, and use of
IV PCA undergoing
general anesthesia
for gynecological
laparoscopic
surgery.25

Level I
Sample size
n = 150

Chaparro et
al,27 (2010)

To evaluate
haloperidol’s
efficacy in
PONV
prophylaxis as
an agent in
combination
therapy.26

Randomized
doubleblinded
placebocontrolled
trial.
Quasiexperimental
Level II

Randomized
Double-blinded
placebo-controlled
trial evaluating
PONV prophylaxis
using combination
of haloperidol and
dexamethasone
compared to
dexamethasone as
a sole agent.26

Non-smoking
female patients
between 18 – 50
years old with an
ASA classification
of I – II undergoing
general anesthesia
for an ambulatory
plastic/
otorhinolaryngologi
cal procedure.26

Within 2 – 24 hours
postoperatively, subjects in
the haloperidol groups (1 mg
and 2 mg) experienced less
PONV, 22% and 20%
respectively, in combination
with dexamethasone, than
the placebo group that
scored a higher incidence of
PONV at 42%.25 Results
after 24 hours demonstrated
that there was a statistically
significant difference at P =
0.003 in PONV incidence
between haloperidol and
dexamethasone combination
treatment groups versus the
control group, where 29%,
24%, and 54% of
participants experienced
PONV respectively.25
There was no statistically
significant protective effect
for nausea prevention
observed with the
combination therapy at 6 and
24 hours, but the overall
incidence of nausea was
lower in the haloperidol with
dexamethasone group at
22.5% and 41.5%
respectively versus the
dexamethasone group at

The 1 mg and 2 mg
haloperidol doses
were equally effective
in preventing PONV
when given in
conjunction with
dexamethasone and
the combination of
dexamethasone with
haloperidol was more
effective in PONV
prevention than
dexamethasone as a
sole agent.25

Participants who
received
dexamethasone
without haloperidol
experienced inferior
PONV prophylaxis.26
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Sample size
n = 166

Chu et al,28
(2008)

To investigate
haloperidol’s
efficacy in
PONV
prophylaxis as
an agent in
combination
therapy.27

Randomized,
doubleblinded,
placebo, and
positivecontrol study.
Experimental
study
Level I

Randomized,
double-blinded,
placebo, and
positive-control
study evaluating
PONV prophylaxis
using combination
of haloperidol and
dexamethasone
compared to
dexamethasone,
haloperidol,

Female patients
with an ASA
classification of I –
II undergoing
general anesthesia
for laparoscopicassisted vaginal
hysterectomy.27

27.5% and 52.5%
respectively.26 The incidence
of vomiting was reduced at 6
hours and its decreased
incidence became
statistically significant at P <
0.05 at 24 hours with
combination therapy.26 At 6
hours, patients who received
the combination therapy
reported a lower incidence of
vomiting at 15% versus
dexamethasone alone at
26.25%.26 At 24 hours,
patients who received
haloperidol and
dexamethasone experienced
a lower incidence of
vomiting at 21.25% versus
dexamethasone alone at
41.25%.26
The statistically significant
PONV incidences at P <
0.05 between 0 – 24 hours
were the following in
respective groups: 19% with
haloperidol plus
dexamethasone, 36% with
droperidol, 37% with
haloperidol, 38% with
dexamethasone, and 65%
with saline.27

Patients who received
the combination of
haloperidol and
dexamethasone
experienced superior
PONV prophylaxis
compared to other
treatment groups.27
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droperidol, and
saline as sole
agents.27
Wang et al,29
(2012)

To investigate
dexamethasone’s
efficacy in
PONV
prophylaxis as
an agent in
combination
therapy.28

Randomized
clinical trial.
Quasiexperimental
study
Level II

Randomized
clinical trial
comparing PONV
prophylaxis of
dexamethasone
plus haloperidol
with ondansetron
plus
dexamethasone.28

Sample size
n = 400
Female patients
between 18 – 65
years old with an
ASA classification
of I – II undergoing
general anesthesia
for gynecologic,
abdominal, and
orthopedic
surgeries expected
to receive morphine
PCA.28
Sample size
n = 135

Grecu et al,30
(2008)

To investigate
haloperidol’s
efficacy in
PONV
prophylaxis as
an agent in

Randomized,
doubleblinded trial.
Quasiexperimental
study.

Randomized,
double-blinded
trial comparing the
PONV efficacy of
haloperidol in
combination with
ondansetron versus

Male and female
patients with a high
risk for PONV and
at least 18 years old
undergoing general
anesthesia or
combined general

The incidence of PONV
among subjects that received
dexamethasone plus
ondansetron and
dexamethasone plus
haloperidol showed a
significant difference at P <
0.05 when compared to those
who only received
dexamethasone.28 Total
PONV incidence after 24
hours in patients who only
received dexamethasone was
25%, which was higher than
in those who received
dexamethasone plus
haloperidol and
dexamethasone plus
ondansetron with an
incidence of 15% and 13%,
respectively.28
Among patients who
received haloperidol and
ondansetron the following
findings were significant:
90% with complete PONV
response after 60 minutes,
76.2% complete PONV

Both treatment groups
that received
haloperidol or
ondansetron in
combination with
dexamethasone
experienced
diminished PONV
incidence and there
was less need for
rescue anti-emetics
over the course of 24
hours.28 The sole
treatment of PONV
with dexamethasone
was not as efficacious
as combination
therapy with
haloperidol or
ondansetron.28
Combination therapy
with haloperidol and
ondansetron provided
a longer lasting and
efficacious PONV
prophylaxis versus
ondansetron without
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combination
therapy.29

Level II

ondansetron as a
sole agent.29

anesthesia-epidural
in a mixed surgical
population.29
Sample size
n = 268

Feng et al,31
(2009)

To investigate
haloperidol’s
efficacy in
PONV

Randomized,
doubleblinded study.

Randomized,
double-blinded
study comparing
the PONV efficacy

Male and female
patients with an
ASA classification
of I – II undergoing

response after 480 minutes,
10% with nausea at 60
minutes or less, 23.9% with
nausea at 480 minutes or
less, 7.7% needing rescue at
180 minutes or less, and
20.8% needing rescue at 480
minutes or less.29 In
comparison, among patients
who only received
ondansetron, the following
findings were significant:
66.2% with complete PONV
response after 60 minutes,
59.2% with complete PONV
response after 480 minutes,
33.8% with nausea at 60
minutes or less, 42.3% with
nausea at 480 minutes or
less, 24.1% needing rescue
at 180 minutes or less, and
37.6% needing rescue at 480
minutes or less.29 The time
to rescue in those who
received haloperidol plus
ondansetron was 154.4 +
133.8 minutes which was
longer than ondansetron at
75.3 + 82.8 minutes.29
The total PONV incidence
among patients who received
haloperidol plus ondansetron
was 21% at 0 – 24 hours;

haloperidol that was
statistically
significant with a P as
low as < 0.001.29

The combination
treatment of
haloperidol and
ondansetron yielded a
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prophylaxis as
an agent in
combination
therapy.30

Quasiexperimental
study.
Level II

Dağ et al,32
(2019)

To evaluate the
most efficacious
dose of
haloperidol for
PONV
prophylaxis with
the least amount
of side effects.31

Randomized
controlled
trial.
Experimental
study
Level I

of haloperidol in
combination with
ondansetron
compared to the
sole use of each
agent.30

general anesthesia
for laparoscopic
cholecystectomy.30

Randomized
controlled trial
comparing PONV
efficacy of
haloperidol doses
of 0.25 mg, 0.5
mg, 1 mg, and 2
mg to a saline
placebo.31

Female patients
between the ages of
19 and 70 years
with an ASA
classification of I –
II undergoing
general anesthesia
for laparoscopic
abdominal
hysterectomy.31

Sample size
n = 210

Sample size
n = 250

however, there was 39% at 0
– 24 hours for those who
only received haloperidol
and 38% at 0 – 24 hours for
those who only received
ondansetron.30 The complete
PONV response was 79% in
the group that received
haloperidol plus
ondansetron; yet, 62% and
61% in subjects who
received ondansetron and
haloperidol respectively.30

greater PONV
prevention response
and an increase in
patient satisfaction.
Subjects who
received both
haloperidol and
ondansetron suffered
the lowest incidence
of PONV and
required less rescue
analgesics or antiemetics.30

The incidence of nausea
differed 2 hours
postoperatively and was
recorded as statistically
significant at P > 0.008; 28%
of patients in group V given
0.25 mg of haloperidol, 14%
of patients in group IV given
0.5 mg of haloperidol, 14%
in group III given 1 mg of
haloperidol, 4% of patients
in group II given 2 mg of
haloperidol, and 26% of
patients in group I given the
placebo had nausea.31 There
was also a statistically
significant difference at P =
0.000 of nausea incidence
between 2 and 24 hours after

There was a
statistically
significant difference
among treatment
groups; the placebo
group experienced the
highest anti-emetic
need at 40% while the
subjects treated with
haloperidol required
fewer rescue antiemetics.31 The
optimal and
efficacious dosages of
parenteral haloperidol
for PONV range from
0.5 mg to 2 mg.31
Participants in group
II who received the
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surgery; 28% of patients in
group V given 0.25 mg of
haloperidol, 6% of patients
in group IV given 0.5 mg of
haloperidol, 2% in group III
given 1 mg of haloperidol,
4% of patients in group II
given 2 mg of haloperidol,
and 18% of patients in group
I given the placebo had
nausea.31 Two hours
postoperatively, researchers
observed a statistically
significant difference at P =
0.009 among groups
regarding the incidence of
vomiting; 16% of patients in
group V given 0.25 mg of
haloperidol, 10% of patients
in group IV given 0.5 mg of
haloperidol, 6% in group III
given 1 mg of haloperidol,
0% of patients in group II
given 2 mg of haloperidol,
and 20% of patients in group
I given the placebo
experienced vomiting.31
Between 2 and 24 hours after
surgery, groups did not show
a statistically significant
difference at P = 0.218 in
regards to the incidence of
vomiting. It was reported

highest dose of
haloperidol of 2 mg
experienced the
highest level of
patient satisfaction
that was also
statistically
significant at P <
0.05.31
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that 6% of participants who
received 2 mg of haloperidol
in group II, 8% of
participants who received 1
mg of haloperidol in group
III, 14% of participants who
received 0.5 mg of
haloperidol in group IV, and
28% of participants who
received 0.25 mg of
haloperidol in group V
needed an additional antiemetic, which was
statistically significant at P <
0.05.31
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Appendix C: QI Project Consent

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT

“An Educational Module on the Utilization of Haloperidol as a Pharmacological Complement for
Postoperative Nausea and Vomiting Prophylaxis in Adult Surgical Patients”

SUMMARY INFORMATION
Things you should know about this quality improvement project:









Purpose: Educational module to increase anesthesia provider knowledge and attitude on
the utilization of haloperidol as a pharmacological complement for postoperative nausea
and vomiting prophylaxis in adult general anesthesia patients.
Procedures: If you choose to participate, you will be asked to complete a pre-test, watch
a voice over PowerPoint, and then a post-test.
Duration: This will take about a total of 25 minutes.
Risks: The main risks for this quality improvement project are minimal. As with any
educational module, potential minimal risks are mild emotional stress or physical
discomfort from sitting on a chair for an extended period of time.
Benefits: The main benefit to you from this educational module is an increase in
participant knowledge and attitude in utilizing haloperidol as a pharmacological
complement for postoperative nausea and vomiting prophylaxis in adult surgical
patients.
Alternatives: There are no known alternatives available to you other than not taking part
in this study.
Participation: Taking part in this quality improvement project is voluntary. If you
decide to participate you will be 1 of 10 participants.

Please carefully read the entire document before agreeing to participate.
PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to increase
anesthesia provider knowledge and attitude on the utilization of haloperidol as a pharmacological
complement for postoperative nausea and vomiting prophylaxis in adult surgical patients.
DURATION OF THE PROJECT
Your participation will require about 25 minutes of your time. If you decide to participate you will be 1 of
10 participants.
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PROCEDURES
If you agree to be in the project, we will ask you to do the following things:

1. Complete an online 16 question pre-test survey via Qualtrics, an Online survey product for
which the URL link is provided.
2. Review the educational PowerPoint Module lasting 22 minutes.
3. Complete the online 16 question post-test survey via Qualtrics, an Online survey product
for which the URL link is provided.
RISKS AND/OR DISCOMFORTS

The main risks for this quality improvement project are minimal. As with any educational module,
potential minimal risks are mild emotional stress or physical discomfort from sitting on a chair for
an extended period of time.
BENEFITS
The following benefits may be associated with your participation in this project: An increased
understanding of the role of haloperidol as a pharmacologic complement for postoperative nausea
and vomiting (PONV) prophylaxis in adult surgical patients. The overall objective of the program is
to improve the perioperative patient experience by diminishing the incidence of PONV.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project. However, if
you would like to receive the educational material given to the participants in this project, it will be
provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided by law.
If, in any sort of report, we might publish, we will not include any information that will make it possible
to identify you as a participant. Records will be stored securely, and only the project team will have access
to the records.

PARTICIPATION: Taking part in this research project is voluntary.
COMPENSATION & COSTS
here is no cost or payment to you for receiving the health education and/or for participating in this project.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or withdraw your
consent at any time during the project. Your withdrawal or lack of participation will not affect any benefits
to which you are otherwise entitled. The investigator reserves the right to remove you without your consent
at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this research project,
you may contact Xenia Del Pozo at 305-439-8058 at xdelp002@fiu.edu and Dr. Ann Miller at 305-348-4871
anmille@fiu.edu.
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights pertaining to being a subject in this project or
about ethical issues with this project, you may contact the FIU Office of Research Integrity by phone
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at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT

I have read the information in this consent form and agree to participate in this study. I have had
a chance to ask any questions I have about this study, and they have been answered for me. By
clicking on the “consent to participate” button below I am providing my informed consent.
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Appendix E: QI Project Pre-test and Post-test Survey

Pre-test and Post-test Questionnaire:
An Educational Module on the Utilization of Haloperidol as a Pharmacological
Complement for Postoperative Nausea and Vomiting Prophylaxis in Adult Surgical
Patients
INTRODUCTION
The primary aim of this QI project is to improve the knowledge and attitudes of
anesthesia providers pertaining to the utilization of haloperidol in combination pharmacologic
therapy during the perioperative period to decrease the incidence of PONV.
Please answer the questions below to the best of your ability. The questions include
demographic information and knowledge of haloperidol utilization in adult surgical patients.
Questions are either in multiple choice or likert style format and are meant to measure anesthesia
provider knowledge of the efficacy of haloperidol for PONV prophylaxis and the respective
attitude of its application in practice.
PERSONAL INFORMATION
1. Gender:

Male

Female

Other _________

2. Age: _________
3. Ethnicity:
Hispanic

Caucasian

African American

Other _________

4. Position/Title: ____________________________________
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5. Level of education:

Associates Bachelors Masters Doctoral (DNP, DNAP, MD,

EdD)
6. Years of experience:

Less than 1 year

1 to 5

6 to 10

more than 10 years

QUESTIONNAIRE
1. The incidence of postoperative nausea and vomiting can be as high as:
a. 80%
b. 60%
c. 40%
d. 20%
CORRECT ANSWER: a.
2. What is the most efficacious parenteral dose range of haloperidol for PONV
prophylaxis according to most recent literature?
a. 2 – 4 mg
b. 0.5 – 2 mg
c. 0.2 – 0.5 mg
d. 0.2 – 0.7 mg
CORRECT ANSWER: b.
3. What classification of anti-emetic is haloperidol considered?
a. NK-1 receptor antagonist
b. Antihistamine
c. Dopamine D2 receptor antagonist
d. Serotonin 5-HT3 receptor antagonist
CORRECT ANSWER: c.
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4. Haloperidol’s clinical effects can be attributed to what mechanism(s) of action?
(Select all that apply)
a. Works at the area postrema and chemoreceptor trigger zone (CTZ) as D2 receptor
antagonist
b. Sedative properties
c. Blocks dopamine receptors via inhibition of dopamine production on cyclic
adenosine monophosphate (cAMP)
d. Alpha-adrenergic inhibiting properties
e. All of the above
CORRECT ANSWER: e.
5. What population of surgical patients can benefit from PONV prophylaxis with
haloperidol? (Select all that apply)
a. Patients undergoing otorhinolaryngological procedures
b. Patients undergoing ophthalmic procedures
c. Patients undergoing laparoscopic procedures
d. Patients undergoing gynecological procedures
e. All of the above
CORRECT ANSWER: e.
6. What are unpleasant symptoms associated with PONV contributing to considerable
patient morbidity and distress? (Select all that apply)
a. Esophageal rupture
b. Wound dehiscence
c. Aspiration
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d. Dehydration
e. All of the above
CORRECT ANSWER: e.
7. Haloperidol should be excluded from patients presenting with which disease
process(es) or condition(s)? (Select all that apply)
a. Parkinson’s disease
b. Neuroleptic malignant syndrome (NMS)
c. Acute/chronic dysrhythmias
d. QT prolongation
e. All of the above
CORRECT ANSWER: e.
8. Potential side effects of haloperidol at high dosages, such as 35 mg or more, include
(Select 2).
a. QT prolongation
b. Hypertension
c. Torsades de pointes
d. Photophobia
CORRECT ANSWERS: a. & c.
9. Utilization of haloperidol in combination with what other medications have shown
superior PONV prophylaxis? (Select 2)
a. Dexamethasone
b. Promethazine
c. Ondansetron
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d. Droperidol
CORRECT ANSWERS: a. & c.
10. PONV prophylaxis is most efficacious when haloperidol is administered when
intraoperatively?
a. At induction
b. At incision
c. At the termination of surgery
d. At any time
CORRECT ANSWER: d.
11. What is haloperidol’s onset of action for PONV prophylaxis?
a. 15 minutes
b. 30 minutes
c. 45 minutes
d. 60 minutes
CORRECT ANSWER: b.
12. What is haloperidol’s duration of action for PONV prophylaxis?
a. 4 hours
b. 3 hours
c. 2 hours
d. 1 hour
CORRECT ANSWER: a.
13. What is haloperidol’s elimination half-life?
a. 2 – 4 hours
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b. 4 – 6 hours
c. 6 – 12 hours
d. 12 – 35 hours
CORRECT ANSWER: d.
14. How likely are you to administer haloperidol in combination therapy for PONV
prophylaxis?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
15. What is your attitude toward the administration of haloperidol as a complementary
drug to decrease PONV?
a. Very positive
b. Positive
c. Neutral
d. Negative
e. Very negative
16. How likely are you to implement haloperidol into your anesthesia practice?
a. Very likely
b. Likely
c. Unsure
d. Unlikely
e. Very unlikely
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